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This thesis studies the design, synthesis, and optimization of radiopharmaceuticals for 
targeted alpha therapy applications with actinium-225 (225Ac). In Chapter 2, three novel 
radiopharmaceuticals - 2.1 (DOTA-CCZ-N-Me-α-CycMSH), 2.2 (Macropa-CCZ-N-Me-
α-CycMSH), and 2.6 (Macropa-α-CycMSH) for malignant melanoma therapy were labeled 
with 225Ac and evaluated. All three radiopharmaceuticals exhibited excellent in vitro 
stability, while Macropa-CCZ-N-Me-α-CycMSH showed lower tumor uptake and 
moderate normal tissue uptake. In Chapter 3, a total of 5 diaza-18-crown-6 macrocyclic 
ligands (macropa, macropaquin, macroquin-SO3, macrohopo, and macrohopo’) as chelators 
for 225Ac were investigated. Two of the chelators (macrohopo and macrohopo’) which 
contain hydroxypyridinone pendant donor arms are novel and were 
synthesized/characterized in this work. Macropaquin was able to quantitively radiolabel at 
chelator concentrations as low as 10-6 M at ambient temperatures within one hour, while 
chelator macrohopo was unable to achieve 225Ac complexation under any conditions. This 
thesis showcases the complexity of radiopharmeticuals, in particular for 225Ac.  
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Accounting for approximately 30% of Canadians deaths, cancer is the number one 
cause of death in Canada1. There have been significant improvements in early detection 
and treatment options, indicated by decreases of 35% and 20% in mortality rates for males 
and females respectively1. However, the Canadian Cancer Society estimates in 2021, that 
1 in 2 Canadians will develop cancer in their lifetime and 1 in 4 Canadians will die from 
the disease1. As such, innovative methods for better therapeutics and early detection 
methods are of the utmost importance. Current detection methods include laboratory tests, 
biopsy, physical examinations, and image testing2. Therapeutic methods include 
chemotherapy, surgery, immunotherapy, radiation therapy, targeted drug therapy, and 
more2. This thesis focuses on the use of nuclear medicine for the diagnosis and selective 
treatment of cancers.  
1.2. Nuclear Medicine  
Nuclear medicine has become a formidable tool for various medicinal fields 
(cancer, heart disease, neurological disorders, etc.) which relies on the use of radioactive 
nuclides for diagnostic imaging and treatment of diseases. Diagnostic methods use positron 
(𝛽&) emitters and gamma ray (𝛾) emitters. Diagnostic radionuclides emit radiation that 
minimally interacts with biological tissues, allowing them to escape and reach external 
detectors3, while therapeutic applications require radionuclides that can cause cytotoxicity. 
Therapeutic methods can include both internal (targeted internal therapy, brachytherapy, 
etc.) and external therapy (FLASH, proton therapy, etc.). The development and constant 
improvement of radiopharmaceuticals have significantly expanded clinical applications. 
Herein, this thesis focuses on internal targeted radionuclide therapy (TRT). 
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1.2.1. Diagnostics 
The two nuclear medicinal imaging techniques are single-photon emission 
computed tomography (SPECT) and positron emission tomography (PET) (Figure 1.1). 
Unlike structural diagnostic methods (computed tomography (CT), magnetic resonance 
imaging (MRI), ultrasound (US), and x-ray), nuclear medicine allows for functional 
imaging to analyze chemical and biological processes within the body4. Cutting edge 
hybrid imaging simultaneously utilizes both PET/SPECT in conjugation with MRI/CT 
(i.e., PET-CT, SPECT-CT) to get both structural and functional images4.  
 
Figure 1.1: Visual representation of SPECT and PET diagnostics 
PET utilizes positron emitting radionuclides such as fluorine-18 (18F). As the 
nuclide decays, it emits a positively charged beta particle (𝛽&) that travels a short distance 
(3 - 5 mm) within the body until it collides with an electron (negatively charged beta 
particle, (𝛽'))4. This collision, also known as an annihilation will release two 511 keV 
gamma (𝛾) rays that are emitted 180º from one another4. The circular arrangement of PET 
coincidence detectors allows for the simultaneous detection of the two 𝛾 rays4. If the two 
detections are within 12 nanoseconds (ns), it is assumed an annihilation has occurred4. 
With enough annihilation events (106), a 3D image with excellent resolution (2 - 3 mm) 
can be reconstructed5. In addition to higher resolution, PET is more sensitive than SPECT 
with required tracer concentrations of 10-8 to 10-10 M, compared to ~10-6 M5. However, the 
major limitations of PET are high operational costs and a limited number of FDA-approved 
PET radiotracers.  
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SPECT, the older modality utilizes gamma cameras that will detect a gamma (𝛾) 
emission within 100 – 250 keV4. With a powerful computerized calculation system, cross-
sectional images allow for a 3D image to be reconstructed4. Despite lower resolution 
pictures (10 – 14 mm), SPECT is the more commonly used methodology4. One major 
reason is the higher availability; as of 2017, there were 330 SPECT machines, 261 SPECT-
CT machines, and only 51 PET-CT machines in Canada6. The other key reason is the much 
lower operational costs for SPECT compared to PET. Unlike PET which traditionally 
employs cyclotron produced “organic” radionuclides (11C, 18F, 13N, and 15O), SPECT can 
use metallic “inorganic” radionuclides such as technetium-99m (99mTc) and indium-111 
(111In).  
1.2.2. Therapeutics  
 Internal targeted radionuclide therapy (TRT) via the use of radiopharmaceuticals 
is an emerging therapeutic method due to its highly selective nature, non-surgical approach, 
and minimal amounts of required radioactivity. There are three types of radioactive 
particles that can be utilized in TRT – alpha particles (𝛼), beta particles (𝛽'), and Meitner-
Auger electrons (MAE) (Table 1.1). Herein, my focus will be on the use of alpha particles 
for targeted alpha therapy (TAT), a subdivision of targeted radionuclide therapy (TRT).  
Table 1.1:  Radioactive particles that can be utilized in TRT 
Decay Energy  Range  LET (keV/µm) 
𝜶  5 - 9 MeV 40 – 100 µm  50 – 230 
𝜷' 0.05 – 2.3 MeV 0.05 – 12 mm ~ 0.2 
Auger Electrons eV - keV 2 – 500 nm 4 – 26 
LET - linear energy transfer (energy deposited per unit distance) 
Beta Particles (𝜷') 
Beta particles are used for medium – large tumors due to their larger penetration 
depth (0.05 – 12 mm), lower energy deposits (0.05 – 2.3 MeV), and small linear energy 
transfer (LET; the amount of energy deposited per unit distance) of 0.2 keV/µm. This even 
distribution of beta particles in heterogenous tumors results in single-strand DNA 
breakage4,7, which can be repaired through DNA repair pathways. With sub-lethal damage, 
very high doses (up to several gigabecquerel (GBq)/cycle) of 𝛽' radiotherapeutics must be 
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administrated to have therapeutic effects in patients8. Common beta emitters such as 
lutetium-177 (177Lu), yttrium-90 (90Y), and iodine-131 (131I) have been incorporated into 
FDA approved targeted beta therapeutics including but not limited to: [177Lu]Lu-
DOTATATE for neuroendocrine tumors, [131I]NaI for thyroid cancer, and [90Y]Y-
ibritumomab tiuxetan (Zevalin®) for non-Hodgkin’s lymphoma9.  
 
Meitner-Auger electrons (MAE) 
MAEs have very short penetration depth in tissue (2 – 500 nm) and minor energy 
deposits (eV – keV) resulting in a moderate LET of 4 – 26 keV/µm7. The efficacy of MAEs 
is dependent on the ability of the targeting vector to internalize such that the radionuclide 
is localized in the cell nucleus. One benefit of MAEs is their low cellular toxicity in the 
blood or bone marrow during circulation within the body4. This relatively new 
radiotherapeutic method has a limited number of successful preclinical studies and clinical 
applications8,10,11. Initial studies of MAEs investigated conventionally used imaging & 
therapeutic radionuclides such as 111In, 125I, 99mTc, and gallium-67 (67Ga), while new 
unconventional MAE emitting radionuclides such as antimony-119 (119Sb), lanthanum-135 
(135La), and mercury-197m/g (197m/gHg) are being explored8,10.  
 
Alpha particles (𝜶) 
Targeted alpha therapy (TAT) uses alpha emitting radionuclides for small and 
metastatic tumor applications7,12. Alpha particles are highly cytotoxic causing double 
stranded DNA breakage, due to their small penetration depth of 40 – 100 µm, high energy 
(5 – 9 MeV) deposit, and large LET of 50 – 230 keV/µm4,7. Their cytotoxicity potency is 
over 100 times greater than beta emitters, such that it requires less than five DNA hits to 
kill a cell4. In 2013, radium-223 [223Ra]Ra-dichloride (Xofigo®) became the first and to 
date, only FDA-approved targeted alpha therapeutic drug13. Over the past decade, five 
other alpha emitters (actinium-225 (225Ac), bismuth-213 (213Bi), astatine-211 (211At), lead-
212 (212Pb), and thorium-227 (227Th)) have gained significant interest for TAT13.  
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1.3. Construction of Radiopharmaceuticals  
A plethora of radioisotopes can be incorporated into a radiopharmaceutical for 
either therapy or imaging. Generally, the construction of a radiopharmaceutical will be 
governed by the chemical nature of the isotope used – either ‘organic’ (e.g., 11C, 18F) or 
‘inorganic’/metallic (e.g., 68Ga, 111In). The focus of this thesis is the use of metallic 
radioisotopes (aka radiometals) – in particular, the emerging alpha-emitter actinium-225 
(vide infra), as such the construction of a metallic radiopharmaceutical will be discussed. 
Typically, radiometal-based radiopharmaceuticals consist of four main components;  
I) Chelator – provides radionuclide stability through metal-chelator 
binding 
II) Linker – connects the chelator to the targeting vector  
III) Targeting vector – a biomolecule with selective binding for over-
expressed tumor receptors 
IV) “Inorganic” radionuclide – provides the radioactive emission for 
therapy/imaging  
Each component is meticulously chosen as radiopharmaceuticals must be 
thermodynamically stable, chemically inert, and fairly easy/inexpensive to synthesize. 
They also must have quick tumor uptake and fast clearance from non-target tissues to 
achieve high tumor-to-background ratios, which ensures reduced radiation exposure to 
healthy tissues4.  
1.4. Chelators  
Chelators are an essential component of metal-based radiopharmaceuticals. When 
designing a chelator, radiometal properties such as the ligand donor atom preferences 
(based on hard-soft-acid-base theory) and coordination number/geometry need to be 
considered14. Chelators can be divided into two types: macrocyclic (closed chain) and 
acyclic (open chained). Macrocyclic ligands are normally more kinetically inert and 
thermodynamically stable than acyclic ligands, due to a phenomenon known as the 
macrocyclic effect14. Yet, macrocycles often require heating at extended times for 
quantitative radiolabeling14. The widely adopted bifunctional chelator (BFC) method 
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utilizes a chelator that I) can bind radionuclides and II) has reactive functional groups that 
can be covalently coupled to targeting vectors (vide infra). With long synthetic alterations 
of the linker, chelate, and biomolecule performed before radionuclide introduction, 
unnecessary decay of the precious radiometal can be avoided (Figure 1.2). The most 
attractive quality of the BFC technique is it allows for a countless number of different 
targeting vectors to be conjugated to limitless numbers of chelators. 
 
Figure 1.2: Illustration of a radiometal-based radiopharmaceutical containing 
bifunctional chelator (BFC) 
1.4.1. Acyclic Chelators  
DTPA (diethylenetriaminepentaacetic acid, N3O5), is one of the most widely used 
acyclic chelators in radiochemistry (Figure 1.3). While it can quantitatively radiolabel 
many radiometals (111In, 177Lu, copper-64 (64Cu), 86/90Y, 68Ga, 213Bi, and zirconium-89 
(89Zr)) at room temperature quickly, it can suffer from low in vivo stability. Nevertheless, 
DTPA has been successful as I) 2 FDA approved SPECT agents - OctreoScanTM and 
ProstaScint® ([111In]In-DTPA-octreotide (OC) and [111In]In-DTPA-capromab 
respectively), II) FDA approved 𝛽' therapy Zevalin® ([90Y]Y-ibritumomab tiuxetan), and 
III) MRI gadolinium (Gd) contrast agents.  
CHX-A”-DTPA (2-(p-isothiocyanatobenzyl)-cyclohexyldiethylenetriamine-
pentaacetic acid, N3O5), a second-generation acyclic chelator has shown improved stability 
and kinetic inertness, a result of the chiral cyclohexyl motif in the DTPA backbone (Figure 
1.3). CHX-A”-DTPA has been thoroughly investigated for 90Y, 111In, 213Bi, and 177Lu, and 
promising clinical trials are underway15.  
1.4.2. Macrocyclic Chelators  
TETA (1,4,8,11-Tetraazacyclotetradecane-1,4,8,11-tetraacetic acid, N4O4), an 
octadentate chelator was only heavily investigated for 64Cu radiopharmaceuticals (Figure 
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1.3). In 2001, one clinical trial found [64Cu]Cu-TETA-OC as a potential PET tracer for 
neuroendocrine tumors16. However, newer generation chelators (i.e. NOTA and TETA 
derivatives) which have improved in vivo stability have replaced older generation TETA14.  
NOTA (1,4,7-Triazacyclononane-1,4,7-triacetic acid, N3O3), a hexadentate 
chelator is the current gold standard for complexation of 68Ga and 64Cu, exhibiting 
favourable radiolabeling conditions and excellent in vivo stability14 (Figure 1.3). As 68Ga 
and 64Cu gain significant interest as PET imaging agents, new promising chelators have 
arisen. However, due to the commercial availability of NOTA and its bifunctional 
analogues, NOTA is still considered the “practical” gold standard14. 
DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, N4O4) a tetraaza 
macrocyclic chelator, is the current gold standard for complexation of several trivalent 
radiometal ions (111In, 177Lu, 86/90Y, 225Ac, and 44/47Sc)17 (Figure 1.3). DOTA can form 
kinetically inert complexes but at the expense of slow radiolabeling kinetics and elevated 
temperatures (60 – 90 °C), which makes conjugation to heat sensitive targeting vectors (i.e. 
antibodies) quite challenging18. Despite conjugation issues, DOTA and DOTA derivatives 
have been incorporated as chelates into more than 50 clinical trials for PET imaging, 𝛽' 
therapy, and/or 𝛼 therapy.  
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Figure 1.3: Structures of acyclic (CHX-A”-DTPA and DTPA) and macrocyclic 
(TETA, NOTA, and DOTA) chelators discussed 
1.5. Linkers  
Linkers, the connector between chelators and the targeting vector are also a critical 
component as they can affect the pharmacokinetics of the radiopharmaceutical. Linkers 
can be classified into four categories i) cationic, ii) anionic, iii) neutral, or iv) metabolically 
cleavable19. Common linkers include polyethylene glycol (PEG) to slow excretion through 
the hepatic system, long hydrocarbon chains increasing lipophilicity, and peptide 
sequences to improve hydrophilicity19. Studies have shown modifying the linker can 
significantly impact the biodistribution of radiotracers19–22. For example, the introduction 
of a cationic piperidine linker allowed for rapid in vivo clearance and increased tumor 
uptake when compared to neutral 8-aminooctanoic acid (Aoc) peptide linker and neutral 
PEG linker for preclinical melanoma imaging with 68Ga and 18F23,21. By modifying 
pharmacokinetics of linkers, higher tumor uptake while minimizing undesired organ 
uptake can be obtained.  
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1.6. Targeting Vectors/Biomolecules  
The choice of targeting vector is crucial, as it will determine the biodistribution and 
pharmacokinetics of radiopharmaceuticals. Ideally, biomolecules must have a high affinity 
for receptors that are over-expressed on diseased cells yet minimally expressed (or are 
absent) on healthy cells. Moreover, the targeting vector’s biological half-life should match 
the physical half-life of the selected radionuclide, exhibit high in vivo stability and minimal 
renal accumulation. Targeting vectors used in radiopharmaceutical design can be 
categorized into one of 3 classes: antibody, peptide, and other. Each class of targeting 
vector will have different biological/physiological properties, advantages, and 
disadvantages.  
1.6.1. Antibodies 
Antibodies, also known as an immunoglobulin are large Y-shaped proteins crucial 
to immune systems. With an average weight of 150 kDa and relatively large size, 
antibodies are slow to circulate and have long biological half-lives. The major benefit of 
antibodies is their highly specific nature allowing for selective tumor localization. 
However, antibodies have slow clearance rates which can cause high radiation doses to 
healthy tissue, resulting in moderate tumor-to-background ratios24. One tactic to mitigate 
this issue is a pre-targeting approach, wherein the targeting vector and cytotoxic 
radionuclide are administered separately (vide infra)24. Another method is the use of 
smaller bioconjugates such as peptides or antibody fragments.  
1.6.2. Peptides 
Similar to antibodies, peptides offer numerous advantages for 
radiopharmaceuticals, including high tumor uptake and a vast number of biological targets. 
Additionally, peptides experience rapid clearance from the blood/non-target tissues due to 
their significantly smaller size (2-20 amino acids)25. Endogenous peptides are known to be 
metabolically unstable, yet synthetic modifications to improve pharmacokinetics and slow 
degradation without altering receptor affinity are well developed3. Moreover, solid-phase 
peptide synthesis allows for easy preparation of peptides with diverse modifications. The 
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major disadvantage of peptides is their excessively rapid clearance can prevent sufficient 
tumor uptake3.  
1.6.3. Others 
Other bioconjugates utilized in radiopharmaceuticals can include nanoparticles 
(NP) and antibody fragments. The biodistribution of nanocarriers is primarily driven by 
their large size and shape, although they can be modified with targeting vectors (peptides 
and antibodies) to increase tumor uptake26. For nanocarriers without targeting vectors, they 
rely on passive targeting, such as the Enhanced Permeability and Retention (EPR) effect26; 
wherein defective vascularization and ineffective lymphatic drainage of tumors allows for 
large carriers to be trapped and accumulated in tumor tissue26. Nanoparticles are 
predominantly excreted through the hepatic system due to their large size, which can cause 
unwanted high liver uptake13. Antibody fragments have superior tumor penetration depth 
and rapid blood clearance while maintaining high receptor affinity24,27,28. However, similar 
to peptides, rapid blood clearance of antibody fragments has been associated with reduced 
tumor uptake24,27,28. 
1.7. Radionuclides 
A radionuclide is an unstable atom that undergoes decay, emitting radiation to 
become stable. Radionuclides used in the nuclear medicine field should have high 
radionuclidic, radiochemical, and chemical purity4. Ideally, the radioisotope should be 
carrier-free (every atom is radioactive) or have a high specific activity (activity per unit 
mass)4. Additionally, the radionuclide half-life (t1/2) should match the biological half-life 
of the targeting vector. For example, antibodies that can take up to days to circulate are 
best matched with long lived radioisotopes. For therapeutic isotopes, the emission of 
gamma rays (in optimal energy ranges) as the radioisotope undergoes decay is valuable as 
low-dose imaging can be performed to determine the distribution of the 
radiopharmaceutical for non-invasive dosimetry determination.  
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1.8. Conjugation 
Conjugation between targeting vectors and bifunctional chelators is dependent on 
the bioconjugation handles on both the linker and the chelator (Figure 1.4). Common 
conjugation techniques include14:  
I) Carboxylic acid and a primary amine coupling with a coupling reagent  
II) Activated esters and a primary amine coupling 
III) An isothiocyanate and a primary amine coupling 
IV) Inverse Electron-demand Diels-Alder (IEDDA) “click” between a 
tetrazine and transcyclooctene  
V) Copper catalyzed “click” between an azide and an alkyne  
 
Figure 1.4: Depiction of conjugation methods discussed in this thesis 
Bioconjugation must be specific to the available handle, not decrease the binding 
affinity of the chelate to the radioisotope, and should occur rapidly at mild conditions14. 
The “click” methodology between tetrazine (Tz) and transcyclooctene (TCO) is rapidly 
gaining interest as the quick metal-free reaction allows for pre-targeting methods14. For 
pre-targeting, the antibody with a TCO handle is introduced into the patient, allowing the 
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antibody adequate time to circulate and accumulate (Figure 1.5). Once accumulated at the 
tumor, a complimentary chelated radionuclide with a Tz handle is administered. In vivo, a 
rapid “click” reaction between TCO-Tz forms the intact radiopharmaceutical, followed by 
rapid clearance of excess radioligand.  
 
Figure 1.5:  Depiction of pretargeted radioiummunotherapy approach (PRIT) 
1.9. Special considerations for α-emitting radiopharmaceuticals  
1.9.1. Recoiling Daughters 
Upon the decay of an α-emitting radioisotope, the daughter nuclide experiences 
recoil energy. To conserve momentum, the daughter nuclide will recoil 180 º from the alpha 
particle. The heavier daughter nuclide will experience a significantly smaller amount of 
energy (100 – 200 keV) compared to the lighter, highly energetic (5 – 9 MeV) alpha 
particle. The recoil energy of a daughter nuclide is calculated using the equation below, 
where 𝑚, is the mass of the alpha particle, 𝑚-./012 is the mass of the daughter nuclide and 





The recoil experienced is 100 - 1000 times stronger than chemicals bonds, resulting 
in the release of the bound daughter7. Consequently, the unchelated daughters, which are 
often radioactive in themselves, can redistribute through the body providing radiation to 
undesired organs. Redistribution will be affected by I) distance covered during the recoil, 
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II) intrinsic affinity of the radionuclide for specific organs, III) active transport, and IV) 
diffusion processes7,30. 
 
Redistribution of recoiling daughters 
Redistribution of recoiled daughters can be difficult to measure and is therefore 
mostly studied post-mortem ex vivo. Theoretically, recoiled daughters will cover on 
average 100 nm in water26, breaking free of its chelate. As the daughter acquires a new 
position, diffusion processes and active transport will become key30. Diffusion of the now 
free ion will be dependent on the type of medium, as the ion experiences different 
interactions with blood-like medium or cell-like components (extra/intracellular matrix)30. 
The movement of particles in tissues depends on their size, charge, configuration, and the 
physicochemical properties of the medium31. The majority of the time, the recoiled nuclide 
is released into the bloodstream, where the intrinsic affinity of the radionuclide will 
determine its fate.  
One effective solution to redistributed recoiled daughters is the use of short-lived 
α-emitting radionuclides (213Bi or 211At) with simple decay schemes7. However, a short 
half-life can present logistical issues for generator elution, radiolabeling, drug 
administration, and allowing for sufficient circulation time. In addition, longer lived α-
emitting radioisotopes with complex decay schemes offer superior cytotoxicity that is hard 
to replicate7.   
 
Retention of recoiled daughters  
There are several approaches to deal with recoiling daughters currently under 
investigation, herein three approaches are described: I) encapsulation in nanocarriers, II) 
fast tumor accumulation, and III) local administration.  
The use of nanocarriers such as metal-based particles, polymersomes, and 
liposomes has been investigated for recoiled daughter retention26,30,32–39. Liposomes 
(phospholipid vesicle) exhibit insufficient retention (~ 12% of 213Bi) at all sizes between 
100 – 800 nm32. Polymersomes (polymer vesicle) have been examined for encapsulation 
of 225Ac and its daughters through simulations and in vitro studies. In 2011 Thijssen et al., 
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examined polymersomes to retain recoiling daughters via a Monte Carlo simulation26. A 
double-layer polymersome was significantly more effective than a single-layer 
polymersome26. Wang et al., compared previous simulations with in vitro experiments, 
wherein 800 nm polymersomes retain 221Fr and 213Bi fairly well (~70% and ~53% 
respectively)33. However, complex alpha decay schemes results in cascading that soft 
materials such as polymersomes and/or liposomes cannot sufficiently handle. To achieve 
adequate retention, nanocarriers should have non-organic components. Lanthanide-based 
phosphate (LnPO4) nanoparticles have shown some promise in reducing toxicity from 
recoiled 225Ac daughters34 (vide infra).  
The second approach hinges on the radiopharmaceutical rapidly taken up by the 
tumor, minimizing circulation within the body. Internalization promotes the sequestering 
of the targeted radionuclide in the tumor cell’s cytoplasm, leading to a higher accumulation 
of radioactivity in the tumor, compared to nontarget organs35. For example, cyclized α-
Melanocyte-Stimulating Hormone (CycMSH/ αMSH), a disease targeting peptide for 
melanoma skin cancer has shown rapid internalization for various derivatives20. 
Particularly three tracers, [68Ga]Ga-CCZ01048, [68Ga]Ga-CCZ01047, and [68Ga]Ga-
CCZ01056 can internalize ~ 36 - 52 % of total bound activity into B16F10 cells after 30 
minutes20.  
For large, easily accessible tumors local administration of the radiopharmaceutical 
offers a simple solution. Notably, a phase I clinical study with locally injected [213Bi]Bi-
DOTA-substance P into gliomas showed high target site retention40. Moreover, no 
local/systemic toxicity was observed and radiation induced necrosis of the tumor allowed 
subsequent resection40. This innovative methodology allows for possible treatment for 
previously non-operable and non-treatable gliomas. Similar promising results were 
obtained in phase I clinical studies with [212Pb]Pb-labeled trastuzumab41 and [111At]At-
labelled chimeric anti-tenascin C monoclonal antibody (ch81C6)42. However, this 
approach is not feasible for small metastases which cannot be easily localized.  
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1.10. Actinium 
Since the discovery of actinium in 1899, 32 isotopes of actinium have been 
identified - ranging from 205Ac to 236Ac43. Of the 32 isotopes, only two - 227Ac (t1/2 = 21.8 
y) and 228Ac (t1/2 = 6.1 h) - are naturally occurring from the decay of uranium-235 (235U) 
and 232Th respectively43. Despite the spiked interest in actinium-225 for TAT, the 
fundamental chemistry of this element is still poorly understood; an outcome of limited 
supply and all actinium isotopes being radioactive12. With an ionic radius of 1.12 Å 
(coordination number (CN) = 6)12,44 and a +3 oxidation state, actinium is the largest 
trivalent actinide. Recently Ferrier et al., determined the hydration number of Ac3+ to be 
10.9 ± 0.5, with an Ac-OH20 distance of 2.63 Å44. Classified as a “hard” Lewis acid 
(according to the hard-soft-acid-base theory), actinium prefers nonpolarized 
electronegative Lewis bases such as oxygen donors12. As all isotopes of actinium are 
radioactive, it is most commonly compared to La3+ due to their similar ionic radii (1.03 Å; 
CN = 6).  
1.11. Actinium-225 (225Ac3+) 
The promising 225Ac3+ ion has a complex decay scheme, including 4 α decays, two 
ß- decays, and two SPECT appropriate	γ emissions13 as seen in Figure 1.6. These highly 
energetic (5.8 MeV, 6.3 MeV, 7.1 MeV, 5.9 MeV, or 8.4 MeV) α decays allow for 
considerable cytotoxicity per atom of actinium. Moreover, it can generate bismuth-213 
(213Bi), a good candidate for TAT currently in clinical trials13. As a long-lived radionuclide 
(t1/2 = 9.9 days), it is suitable for antibody conjugation13. Within the past decade, there have 
been several noteworthy clinical successes with 225Ac3+-radiopharmaceuticals (vide 
infra)45–54. However, 225Ac-radiopharmaceuticals remain underdeveloped, an outcome of 
limited 225Ac radionuclide supply, an inability to form kinetically inert complexes under 




Figure 1.6:  The decay scheme of Ac-225 with imaging relevant gamma emissions 
in green 
1.11.1. Ac-225 Production 
The current global average production of 225Ac is 63 GBq – the equivalent of only 
1000 patient treatments yearly, yet the estimated current demand for 225Ac is 185 GBq per 
year13. The main source of 225Ac originates from thorium-229 (229Th, t1/2 = 7340 y) 
stockpiles extracted from uranium-223 (223U, t1/2 = 1.6 x 105 y) decay (Figure 1.7)13. The 
key advantage of this method is the isolation of high purity radionuclide with no other 
actinium isotopes present, nevertheless, it fails to meet current demand13. One production 
method under investigation is proton bombardment of radium-226 (226Ra) via the 
226Ra(p,2n)225Ac nuclear reaction13. The promising 226Ra(p,2n)225Ac reaction can produce 
108 Ci (3.9 TBq) monthly with a 1g 226Ra target; however, major safety concerns around 
the highly radioactive target manufacturing, radiation protection, processing, and recycling 
has slowed this potential production method from moving forward13. The other main 
production method under investigation is the spallation of thorium-232 (232Th) targets via 
high energy protons13. With the largest potential monthly production at 11.2 TBq, the major 
disadvantage is the production of dozen of isotopes such as long-lived 227Ac (t1/2 = 21.7 y) 
that requires extensive separation and purification methods13. Production method 
natU(p,x)225Ac produces small amounts of pure 225Ac3+ and mother nuclide 225Ra (which 
can be eluted every 17 days to produce additional 225Ac)13. However, the total produced 
225Ac activity for 2016 was only 44.4 MBq, indicating this production method is 
insignificant compared to the current 229Th generators13.  
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Figure 1.7: The decay scheme of U-233 to Ac-225 
1.11.2. Ac-225 Chelation   
With a lack of fundamental understanding of 225Ac3+ coordination chemistry, 
predicting chemical structures of ligands that complex actinium and exhibit in vitro and in 
vivo stability is difficult. The first studies involved commercially available chelates such 
as EDTA, DTPA, and DOTA that have shown some clinical use13,55–57. Out of the 10 
chelates initially examined (vide infra), only DOTA illustrated quantitative labeling and in 
vivo stability. DOTA quickly became the “gold standard” for the trivalent actinide, leading 
to DOTA-antibody and DOTA-peptide targeted 225Ac-radiotherapeutics.   
Initial studies of [225Ac]Ac-DOTA-antibody conjugates found higher temperatures 
(>60 °C) were required for adequate 225Ac complexation. As antibodies are unstable at 
elevated temperatures (>37 °C), a novel two-step procedure was introduced55. Bifunctional 
DOTA-isothiocyanate (DOTA-NCS) was quickly radiolabelled with 225Ac, followed by 
the conjugation of an antibody yielding an [225Ac]Ac-DOTA-antibody construct55. This 
process was successfully employed for antibodies HuM195, B4, huJ591, mJ591, and 3F855. 
The radiochemical yield was low at 9.8 ± 4.5 %, however, the radiochemical purity was 
>90 % for all constructs with moderate specific activities (4.1 ± 2.6 GBq/g)55. In hopes of 
finding a superior option, Maguire et al., investigated a direct 1-step labeling of antibody-
DOTA constructs at temperatures suitable for antibodies58. Radiolabeling was performed 
at 37 oC for 2 hours with the addition of radiolytic protectant L-ascorbic acid58. 
Remarkably, the radiochemical yield increased 10 fold (~80%) compared to 2-step 
methods (6 - 12%) and up to a 30 fold increase in specific activity (~130 GBq/g)58. 
Currently, no other rapid or mild radiolabeling conditions have been discovered for 225Ac 
radiolabeling with chelate DOTA58. Despite that, DOTA is the chelator of choice for all 
human clinical studies with 225Ac (vide infra –Table 1.3). 
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1.11.3. Ac-225 Recoiling Daughters  
With 4 α decays per atom of actinium, the bio-distribution of each alpha emission 
in 225Ac’s decay chain (Figure 1.6) needs to be evaluated. Nonchelated 225Ac distributes 
primarily to the liver, spleen, and skeleton with some retention in the kidney56 (Table 1.2). 
217At has the shortest half-life (32 ms) of the alpha emitters and is often assumed to have 
identical biodistribution to 221Fr13. The distribution of 213Bi and 221Fr to the renal system 
(kidneys, renal pelvis, bladder, etc.) is the major limitation of 225Ac TAT.  
Table 1.2: Major targeted organs for Ac-225 daughters (t1/2 > 3 min) 
Daughter  Major targeted organs 
Actinium Liver, spleen, skeleton, and kidneys56 
Francium  Primarily kidneys59 
Bismuth Urine, kidneys, and blood59 
Lead Blood, liver, skeleton, and kidneys30 
Encapsulation in nanoparticles has become one of the leading efforts to capture 
225Ac’s recoiling daughters. One study examined the effectiveness of gold coated 
lanthanide phosphate (LnPO4) nanoparticle (NP) to contain the recoiled 225Ac daughters34. 
It hinges on the concept that highly energetic α-particles will only lose <2% of their energy 
in the layered NP, while the recoiling daughter will only travel 20 nm in bulk LnPO434. The 
layered NPs consist of {La0.5Gd0.5}PO4 core with GdPO4 shells coated in gold34. With 4 
GdPO4 shells, retention of 225Ac and daughter 221Fr was excellent at >99.99 % and 88% 
respectively after 3 weeks in vitro34. Moreover, the authors demonstrated antibody 
conjugated NPs retained specific binding affinity of the antibody and significant amounts 
of 213Bi were retained within the NP in various tissues (>70 %)34.  
Jaggi et al., investigated reducing the renal accumulation of unchelated 225Ac 
daughters through the use of metal chelation and diuretics59. Metal chelator 2,3-
dimercapto-1-propanesulfonic acid (DMPS) and meso-2,3-dimercaptosuccinic acid 
(DMSA) were administered orally prior to the injection of [225Ac]Ac-DOTA-lintuzumab 
into mice and monkeys59. DMSA significantly reduced renal 213Bi accumulation (14.8 % 
ID/g (injected dose per gram) reduction, 6 hrs post injection), but was less potent than 
DMPS (31.2 % ID/g reduction, 6 hrs post injection (p.i.)) in doing so59. In contrast, 
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diuretics furosemide and chlorothiazide (known to chelate metals and enhance its 
excretion) minimized the accumulation of both 221Fr and 213Bi59. The combination of 
DMPS with a diuretic caused an excellent reduction of renal 213Bi activity (~75 – 80%)59. 
Preclinically, this study shows metal chelation and diuretics can be used to reduced renal 
accumulation of 225Ac daughters. 
Poty et al., investigated pretargeted α-radioimmunotherapy (PRIT) as an alternative 
strategy to reduce non-specific toxicities for conventional 225Ac α-radioimmunotherapy 
(RIT)60 of pancreatic ductal adenocarcinoma. After 3 days of circulation, tumor uptake for 
both methods were not significantly different (PRIT: 29.6 ± 6.6 % ID/g, RIT: 31.1 ± 21.4 
% ID/g; 3 d p.i.). Conversely, there were significantly higher tumor-to-liver, tumor-to-
bone, and tumor-to-spleen ratios for PRIT compared to conventional RIT. The radionuclide 
daughters’ redistribution was followed by performing ex vivo Cerenkov imaging 
immediately after sacrifice and again after secular equilibrium. The radiance in the kidneys 
dropped ~ 4 fold (from 16,400 p/sec/cm2/sr to 4,900 p/sec/cm2/sr) after reaching 
equilibrium, a result of the free 213Bi, 221Fr, and their 𝛽' daughters accumulating in the 
kidneys. Poty et al., illustrated PRIT is as effective as RIT while reducing off target 
toxicities but neither method significantly limited the redistribution of the 225Ac daughters.  
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1.11.4. Ac-225 Clinical Trials  
 
Figure 1.8:  Structures of radiopharmaceuticals used in clinical trials with 225Ac 
(as of September 15, 2021) 
With a prolonged half-life (t1/2 = 9.9 d), initial 225Ac clinical studies used long-lived 
antibody conjugates such as lintuzumab as disease targeting vectors (Figure 1.8 and Table 
1.3). The first of its kind study was a dose-escalation trial to determine the safety, 
pharmacology, and biological activity of [225Ac]Ac-lintuzumab in Acute Myeloid 
Leukemia (AML)45. Patients with AML have abnormal immature white blood cells (blasts) 
populating over 20% of peripheral/bone marrow cells compared to 1 – 5 % for healthy 
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individuals. [225Ac]Ac-lintuzumab was administrated as 18.5, 37, 74, 111, or 148 kBq per 
kg of body weight doses to 18 patients45. Peripheral blasts were eliminated in 63% of 
patients and bone marrow blasts reductions were observed in 67% of patients45 (for those 
receiving >18.5 kBq/kg doses). However, serious toxicities (grade >3), myelosuppression, 
and death from sepsis occurred in 2 patients receiving 148 kBq/kg (2/2) and 1 patient 
receiving 111 kBq/kg (1/2) dosages45. A subsequent trial treated 18 patients with 18.5 (n = 
3), 37 (n = 6), 55.5 (n = 3) or 74 (n = 6) kBq/kg, diuretic furosemide and low-dose 
cytarabine (LDAC)46. Overall, only 5/18 (28%) patients had complete remission and 
median progression-free survival was 2.7 months.  
Notably, [225Ac]Ac-PSMA-617 (prostate-specific membrane antigen-617) has 
shown remarkable success in clinical trials targeting metastatic prostate cancer51,54,52,50 
Figure 1.8 and Table 1.3). In 2014/2015, two patients with late-stage metastatic castration-
resistant prostate cancer (mCRPC) were offered [225Ac]Ac-PSMA-617 as salvation therapy 
after exhausting conventional therapy options54. Patient A received 3 cycles of 9 - 10 MBq 
of [225Ac]Ac-PSMA-617 (100 kBq/kg of body weight) at bi-monthly intervals, with one 
additional 6 MBq consolidation therapy session54. Patient B received 3 cycles of 6.4 MBq 
of [225Ac]Ac-PSMA-617 (100 kBq/kg of body weight) at bi-monthly intervals54. Two 
months after the last cycle, both patients’ PET/CT scans and laboratory tests (prostate 
specific antigen (PSA) <0.1 ng/mL) indicated they were in complete remission54. A 
subsequent trial in 2015/2016, treated 40 patients with 100 kBq/kg of body weight at bi-
monthly intervals, where 87% of surviving patients had a PSA decline of any degree and 
63% of patients had a PSA decline >50%51. It should be noted, both patients in the first 
study and 10% of the patients in the second clinical trial experienced intolerable 
xerostomia51,54. In another recent clinical trial, 17 chemotherapy-naïve patients with 
advanced metastatic prostate cancer were treated52. The first cycle was 100 kBq/kg of body 
weight with subsequent cycles either increasing, remaining constant, or decreasing activity 
based on patient response52. Remarkably, seventy-one percent (12/17) of patients reported 
a PSA decline of >80% after only the first cycle52. A tolerable grade ½ xerostomia was 
found in all patients, indicating the de-escalation of the administrated dose is a possible 
way to minimize side effects while maintaining therapeutic efficacy52. Another approach 
to mitigate severe xerostomia was evaluated during a tandem study of [177Lu]Lu-PSMA-
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617 with low activity [225Ac]Ac-PSMA-61750. Herein, 20 patients received 1.5 – 7.9 MBq 
of [225Ac]Ac-PSMA-617, followed directly by 5.0 – 11.6 GBq of [177Lu]Lu-PSMA-61750. 
Sixty-five percent (13/20) of patients had a PSA decline of >50%, and xerostomia was mild 
(grade 2) in only 25% (5/20) of patients50. This study suggests tandem therapy with 
[225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 can minimize xerostomia while also 
providing alternative therapeutic options for those who are resistant to [177Lu]Lu-PSMA-
617.  
Table 1.3: Summary of clinical trials with Ac-225 unless otherwise specified (as 
of September 15, 2021) 
Paper 
reference 




mAb Small molecule   
Juric 201145 I 
 
Lintuzumab  20 18.5 to 148 
kBq/kg 
Juric 201646 I Lintuzumab with 
low-dose 
Cytarabine 




I  PSMA-617 2 100 kBq/kg  
Kratochwil 
201851 
I  PSMA-617 40 100 kBq/kg 
Sathekge 
201952 
I  PSMA-617 17 100 kBq/kg†  
Sathekge 
202053 
I/II  PSMA-617 73 100 kBq/kg† 
Khreish 
202050 
I  225Ac-PSMA-617 
with 177Lu-PSMA-
617 
20 60 kBq/kg  
Ballal 202047 I  DOTATATE 32 100 kBq/kg 
Zhang 
202048 
I  DOTATOC 1 9.8 MBq 
Królicki 
202149 
I  DOTA-SP 21 10, 20, or 30 
MBq 
† patients originally received 100 kBq/kg and subsequent doses were determined based on patient response.  
Currently, there are 4 [225Ac]Ac-lintuzumab clinical studies in progress or actively 
recruiting; other 225Ac clinical trials actively recruiting include: [225Ac]Ac-JNJ-69086420 
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for advanced prostate cancer, [225Ac]Ac-FP1-1434 for advance solid tumors15. With 
promising phase I/II 225Ac clinical results and several 225Ac clinical trials currently 
underway, the development of chelators that can form kinetically inert 225Ac complexes 
under ideal conditions (quick kinetics and mild temperatures) with favourable 
biodistribution is essential.  
1.12. Thesis Overview 
This thesis presents the design, synthesis, and optimization of radiopharmaceuticals 
for targeted alpha therapy applications with actinium-225. Chapter 2 reports three novel 
radiopharmaceuticals: 2.1 (DOTA-CCZ-N-Me-α-CycMSH), 2.2 (Macropa-CCZ-N-Me-α-
CycMSH), and 2.6 (Macropa-α-CycMSH) for targeted alpha therapy of malignant 
melanoma. Specifically, chapter 2 investigates the effect of choice of chelate and targeting 
vector/linker modifications on 225Ac complexation, in vitro stability, and biodistribution of 
225Ac-radiopharmaceuticals. Chapter 3 reports the synthesis and characterization of two 
novel macrocyclic chelators (3.6 and 3.12) and their subsequent ability to complex 225Ac. 
By directly comparing these novel chelators with previously reported chelators, the impact 
of donor arms on diaza-18-crown-6 ligands as chelators for 225Ac is investigated.  
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Chapter 2.  
 
Evaluating αMSH radiopharmaceuticals for 225Ac targeted 
alpha therapy  
2.1. Introduction 
With over 80,000 cases a year in Canada, skin cancer is the most diagnosed cancer 
with more cases than breast, prostate, lung, and colon cases combined61. Skin cancer is 
categorized into two main types: melanoma skin cancer and non-melanoma skin cancer. 
Non-melanoma skin cancer includes basal cell carcinoma (BCC) and squamous cell 
carcinoma (SCC), which account for ~95 - 99% of all skin cancers62. While melanoma skin 
cancer only accounts for 1 - 5% of diagnosed skin cancers, it causes the majority of skin 
cancer related deaths63. For cancers that tend to metastasize such as malignant melanoma, 
early diagnosis and treatments are crucial for long-term survival63. Early-stage melanoma 
skin cancer has a 5-year survival of 88%, while late-stage melanoma has a 5-year survival 
rate of only 34%1. Diagnostic options include biopsy, ultrasound, CT, MRI, PET, and PET-
CT63. Dependent on the stage of melanoma, treatment possibilities include surgically 
removing the melanoma (best for local, early-stage melanoma), radiation therapy used as 
adjuvant treatment, or oral medications/IVs for late-stage developments including 
immunotherapy, chemotherapy, and/or targeted therapy63.  
As malignant melanoma is one of the most resistant cancers to conventional 
chemotherapy, the development of immunotherapy and targeted therapy is of great 
interest64. Several specific markers for malignant melanoma cells have been studied64. With 
expression in nearly all melanomas (>80%) and low expression levels in normal tissues, 
melanocortin 1 receptor (MC1R) has been the focus antigen for melanoma targeted 
imaging and therapy64. The melanocortin (MC) family consists of five melanocortin 
receptors (MC1R to MC5R) that belong to G protein-coupled receptors64. Alpha-
melanocyte stimulating hormone (α-MSH), a tridecapeptide is a non-selective naturally 
occurring ligand to the MC family of receptors (except MC2R)64. Impressively, α-MSH 
binds to MC1R with subnanomolar binding affinity (Ki = 0.23 nM)65. However, as an 
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endogenous peptide, α-MSH is subject to degradation in vivo. Over the past decade, α-
MSH derivatives with improved in vivo stability and binding affinity to MC1R have been 
investigated20,35,64. The most promising α-MSH analogues contain lactam cyclization and 
unnatural amino acid substitution23 (Nle4-cyclo[Asp5-His6-D-Phe7-Arg8-Trp9-Lys10]; Nle-
CycMSH) as illustrated in Figure 2.1. 
Development and optimization of Nle-CycMSH based conjugates with chelator 
DOTA and series of linkers have been investigated for imaging20–23. The introduction of 
cationic piperidine linker allowed for high tumor uptake and rapid in vivo clearance for two 
derivatives ([68Ga]Ga-CCZ0104823 and [18F]CCZ0106420). To date, only two studies 
investigated emerging radionuclide 225Ac for possible melanoma targeting therapy with a 
Nle-CycMSH derivative66,67. Both studies used the same Nle-CycMSH based peptide with 
piperidine linker, but the chelate of choice differed, Ramogida et al., evaluated gold 
standard DOTA66 while Yang et al., evaluated novel crown67 chelate (Figure 2.1). In vivo 
biodistribution of [225Ac]Ac-DOTA-α-CycMSH revealed moderate tumor uptake (5.2 ± 
1.8% ID/g) 2 hours post injection. In vivo biodistribution of [225Ac]Ac-crown-α-CycMSH 
revealed higher tumor uptake (12.7 ± 2.3% ID/g) 2 hours post injection.  
 
Figure 2.1:  Structures of I) endogenous alpha-melanocyte stimulating hormone 
(α-MSH), II) Nle-CycMSH (an α-MSH analogue), III) DOTA-α-
CycMSH, and IV) crown-α-CycMSH 
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2.2. Aim of the Project 
Many tactics have been investigated for increasing tumor uptake and in vivo 
stability, reducing off-target uptake, and exhibiting rapid in vivo clearance20–22,67–69. 
Herein, I investigate the effect of some of those tactics with three novel radiotracers: 2.1 
(DOTA-CCZ-N-Me-α-CycMSH), 2.2 (macropa-CCZ-N-Me-α-CycMSH), and 2.6 (VB-
02-32/ macropa-α-CycMSH). The intrinsic characteristics of a chelator such as 
lipophilicity, charge, and coordination number can significantly impact the biodistribution 
of radiopharmaceuticals67. As such, I evaluate 2.6, a macropa-α-CycMSH derivative - a 
direct comparison to DOTA66 and crown67. Two novel tracers: 2.1 (DOTA) and 2.2 
(macropa) contain slight linker and targeting vector modifications when compared to 2.5 
to allow for longer blood circulation, theoretically increasing radiation dose delivery to 
tumor sites68 (Figure 2.2). Due to patent protection, the structures of 2.1 and 2.2 cannot be 
disclosed. In this chapter, the ideal radiolabeling conditions, in vitro stability, and/or in 




2.3.1. Synthesis Methodology 
 
Scheme 2.1:  Synthetic route of novel macropa-α-CycMSH bioconjugate 2.6 
Both 2.1 (DOTA-CCZ-N-Me-α-CycMSH) and 2.2 (Macropa-CCZ-N-Me-α-
CycMSH), were synthesized and characterized by Dr. Chengcheng Zhang at British 
Columbia Cancer Agency (BCCA). Peptide 2.5 was synthesized and characterized by Dr. 
Chengcheng Zhang at British Columbia Cancer Agency (BCCA). 2.6 (macropa-α-
CycMSH) was synthesized following a modified procedure as per Thiele et al.17 as shown 
in Scheme 2.1. Precursor macropa-NH2 (2.3) was provided as a trifluoroacetic acid (TFA) 
salt by the Wilson group at Cornell University. Functionalization of 2.3 with thiophosgene 
and sodium carbonate in dry acetone formed the isothiocyanate 2.4. Due to substantial 
light, moisture, and temperature sensitivity of 2.4, the crude product was immediately 
carried forward to the next reaction after a quick workup. Conjugation of crude 2.4 and 
purified 2.5 (CCZ01048 peptide) yielded novel macropa-α-CycMSH bioconjugate 2.6, 
which was purified via semi-preparative high performance liquid chromatography (HPLC) 







































































































2.3.2. Actinium-225 radiolabeling and in vitro stability 
Ideal radiolabeling conditions yield high specific activity products under mild 
temperatures (ambient – 40°C), quickly (<15 min is ideal) and with high (>90%) 
radiochemical yield. By adjusting the pH and temperature of the reaction, ideal 
radiolabeling conditions for 2.1, 2.2, and 2.6 (molar activity, M.A. = 20 kBq/nmol of 
ligand) were developed for low amounts of 225Ac (<100 kBq). 2.1, a DOTA construct 
requires elevated temperatures (85ºC) for 1 hr and a pH of ~ 6 to obtain quantitative 
radiochemical yield (RCY). When reaction temperatures were lowered to 75ºC and 65ºC 
insufficient complexation was achieved (between 18 – 42% RCY). Conversely, the 
macropa-CCZ-N-Me-α-CycMSH (2.2) derivative proved to be robust, with >99% RCY at 
ambient temperatures (25ºC) within 1 hr for a wide range of pHs (5 – 7). Macropa-α-
CycMSH (2.6) was able to quantitatively label using the same conditions as macropa-CCZ-
N-Me-α-CycMSH (pH ~ 6, 1 hr at ambient temperature).  
Radiopharmaceuticals must be kinetically inert, such that when injected into 
patients the radionuclide is not transchelated with endogenous proteins within the blood. 
To determine the in vitro stability of 2.1, 2.2, and 2.6, the radiometal-complexes were 
challenged with human serum (3:1 serum to:radiometal-complex) over 10 days. The results 
for the stability of [225Ac]Ac-DOTA-CCZ-N-Me-α-CycMSH), [225Ac]Ac-macropa-CCZ-
N-Me-α-CycMSH, and [225Ac]Ac-macropa-α-CycMSH are compiled in Table 2.1. All 
three tracers show excellent stability in vitro, remaining >90% intact after 7 days. While 
complex stability in vitro can indicate the kinetic inertness, caution must be taken as in 
vitro studies rarely accurately predict in vivo stability of the radiopharmaceutical70. As 
such, further studies to determine in vivo stability and biodistribution are warranted.  
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Table 2.1: Summary of 10-day in vitro human serum stability assay for novel 
radiotracers, with all reported data as % RCY (intact) at that specific 
time point (n = 3 for each data point) 
 1 H 1D 3D 4D 5D 7D 8D 10D 








 2.2 >99  >99 >99 >99 N.D* >99 N.D* >99 





* N.D – no data  
2.3.3. Biodistribution Results  
Biodistribution studies require high purity, carrier-free 225Ac extracted from 
uranium-233 (223U, t1/2 = 1.6 x 105 y) decay (source A, vide infra). With limited pure 
radionuclide supply, the biodistribution of only 2.1 and 2.2 were investigated herein.  
2.1 was precluded from in vivo studies due to low % RCY (<10%) during 
radiolabeling with high amounts of 225Ac (8.71 MBq). As such, the biodistribution of 
[225Ac]Ac-macropa-CCZ-N-Me-α-CycMSH (M.A = 1.38 MBq/nmol) was evaluated for 
two different injected radioactivities. A total of 8 (n = 4) B16F10 tumor bearing mice were 
injected with either dose 1 (103.6 kBq/75 pmol of ligand) or dose 2 (51.8 kBq/37.5 pmol 
of ligand). After two hours post injection (2 hr p.i.), all mice were sacrificed, and the 
harvested organs of interest were measured immediately after sacrifice and after secular 
equilibrium was met (>6 hr). As there was no statistical difference between time points, 
results are reported after equilibrium was met. [225Ac]Ac-macropa-CCZ-N-Me-α-
CycMSH demonstrated quick excretion through the renal system, with moderate-to-high 
uptake in the bladder, kidneys, and urine. Moderate off-target uptake was observed for the 
spleen (1.85 ± 0.64% ID/g), blood (2.13 ± 0.33 % ID/g), and gall bladder (3.35 ± 0.66 % 
ID/g), while more significant uptake was seen in the liver (5.93 ± 0.4 % ID/g). Tumor 
uptake was low at 2.50 ± 0.49 and 0.67 ± 0.11 % ID/g for dose 1 and dose 2 respectively 
(see Figure 2.2). With low tumor and moderate off-target uptake, [225Ac]Ac-macropa-
CCZ-N-Me-α-CycMSH demonstrates poor tumor-to-normal tissue ratios (Table 2.2).   
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Figure 2.2: Biodistribution of [225Ac]Ac-macropa-CCZ-N-Me-α-CycMSH at 2 hr 
post-injection for dose 1 (103.6 KBq/75 pmol of ligand) and dose 2 
(51.8 kBq/37.5 pmol of ligand) in B16F10 tumor bearing mice 
Table 2.2: Summary of tumor-to-normal tissue ratios for [225Ac]Ac-macropa-
CCZ-N-Me-α-CycMSH at 2 hr post-injection for dose 1 (103.6 KBq/75 
pmol of ligand) and dose 2 (51.8 kBq/37.5 pmol of ligand) 










Dose 1 2.50 ± 0.49 0.88 ± 0.16 1.17 ± 0.18 0.42 ± 0.07 1.80 ± 0.46 0.78 ± 0.24 
Dose 2 0.67 ± 0.11 
 
0.71 ± 0.21 
 
0.73 ± 0.12 
 
0.40 ± 0.05 
 
1.03 ± 0.21 0.33 ± 0.24 
*all results are reported as %ID/g, measured in window A (80 – 120 keV) 
One explanation for the low tumor uptake is the sub-optimal radiopharmaceutical 
preparation and formulation conditions: I) [225Ac]Ac-macropa-CCZ-N-Me-α-CycMSH 
was prepared the day before injection, allowing for significant radiolysis and 2) purification 
of the tracer was performed via Sep-Pak (compared to HPLC purification). In a recent 
study, the optimal preparation and formulation of [225Ac]Ac-crown-α-CycMSH was 
evaluated by varying the time of preparation, purification of tracer, and addition of 
radiolytic protectant L-ascorbate67. The construct prepared the day before injection, even 
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with the addition of L-ascorbate was low (4.84 ± 3.2 % ID/g). Constructs prepared the 
same day as injection with L-ascorbate saw a dramatic increase in tumor uptake (12.7 ± 
2.3 % ID/g). Moreover, the tracers prepared the same day as injection had minimal uptake 
in non-target tissues, leading to superior tumor-to-blood, bone, and kidney ratios. 
Radiolysis of [225Ac]Ac-macropa-CCZ-N-Me-α-CycMSH could lead to peptide 
degradation resulting in low tumor uptake or destroy the chelator encapsulating 225Ac. 
Consequently, the intrinsic affinity of unbound 225Ac can cause high off-target uptake in 
the liver, spleen, skeleton, and kidneys56. Another possible explanation for off-target 
uptake in the urine, kidneys, and blood is the intrinsic affinity of the ejected radioactive 
daughters 221Fr and 213Bi for these organs (vide supra - Table 1.2). The purification of the 
tracer via HPLC, the addition of a radiolytic protectant, and/or immediate injection could 
minimize degraded [225Ac]Ac-macropa-CCZ-N-Me-α-CycMSH being injected into the 
mouse, ultimately increasing tumor uptake and decreasing off-target uptake.  
2.4. Conclusion & Future Work 
In chapter 2, three novel radiopharmaceuticals for malignant melanoma therapy, 
2.1 (DOTA-CCZ-N-Me-α-CycMSH), 2.2 (macropa-CCZ-N-Me-α-CycMSH), and 2.6 
(macropa-α-CycMSH) were examined. Macropa constructs (2.2 and 2.6) were robust with 
>99% RCY at ambient temperatures for a wide range of pHs (5 – 7), whereas DOTA 
construct 2.1 required elevated temperatures (85 ºC) for 1 hr to obtain a quantitative 
radiochemical yield. The kinetic inertness was studied in vitro via a human serum stability 
assay, wherein all three radiopharmaceuticals exhibited favourable stability with >90% 
RCY after 7 days. The biodistribution of [225Ac]Ac-macropa-CCZ-N-Me-α-CycMSH was 
investigated for two doses (103.6 KBq/75 pmol of ligand or 51.8 kBq/37.5 pmol of ligand). 
Tumor uptake was low at 2.50 ± 0.49 and 0.67 ± 0.11 % ID/g for dose 1 and dose 2 
respectively, while off-target uptake was moderate leading to low tumor-to-normal tissue 
ratios. A possible explanation for low tumor & moderate normal tissue uptake is the 
preparation and formulation of [225Ac]Ac-macropa-CCZ-N-Me-α-CycMSH, but further 
studies need to be performed to confirm. Many tactics have been investigated for increasing 
tumor uptake and in vivo stability, reducing off-target uptake, and exhibiting rapid in vivo 
clearance20–22,67–69. As intrinsic characteristics of a chelator and linker can significantly 
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impact the biodistribution of radiopharmaceuticals67, this chapter aimed to study those 
effects in vivo.  
Future work for this project is dependent on the purity of supplied 225Ac. If high 
purity, carrier-free 225Ac extracted from uranium-233 is available, further animal studies 
can be performed. Specifically, an in vivo biodistribution study of 2.2 and 2.6, wherein 
[225Ac]Ac-macropa-CCZ-N-Me-α-CycMSH and [225Ac]Ac-macropa-α-CycMSH are 
prepared the day of injection, with L-ascorbate, and purified via HPLC, should be 
conducted in the future. The biodistribution evaluation of 2.6 is a direct comparison to 
[225Ac]Ac-crown-α-CycMSH and [225Ac]Ac-DOTA-α-CycMSH investigating the effect of 
chelator choice on in vivo biodistribution. The biodistribution of [225Ac]Ac-2.2 prepared 
with optimized radiopharmaceutical preparation and formulation conditions will provide 
experimental reasoning for the low tumor uptake and high non-target tissue of [225Ac]Ac-
macropa-CCZ-N-Me-α-CycMSH. 
2.5. Experimental  
2.5.1. Materials and Methods 
All solvents and reagents were purchased from commercial suppliers (TCI 
America, Fisher Scientific, Macrocyclic, and Sigma Aldrich). Solvents noted as “dry” were 
obtained following storage over 3 Å molecular sieves. 1H and 13C NMR spectra were 
referenced to the residual solvent peak and recorded at 25 oC (unless noted otherwise) on 
Bruker AV400, AV500, or AV600 instruments. Deionized water (>18 MΩ cm) was used 
via Millipore-Direct (Milli-Q IQ 7000) purification. High-resolution electrospray-
ionization mass spectrometry (HR-ESI-MS) was performed on an Agilent 6210 time-of-
flight instrument (TOF). The semi-preparative HPLC used for the purification of non-
radioactive compounds was an Agilent 1100 series consisting of a G1311A Quaternary 
Pump, G2260A autosampler, and G1315B variable wavelength absorbance detector. 
Purification was performed with a Kinetex semi-preparative C18 column, 5 µm, 100 Å, 
150 x 10.0 mm at a flow rate of 3.0 mL/min unless otherwise noted. Gradient HPLC 
methods utilized a binary mobile phase that contained H2O with 0.1 % TFA (A) and 
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Acetonitrile (CH3CN) with 0.1 % TFA (B). HPLC Method 2A: 10% B (0 – 5 minutes), 10 
– 100% B (5 – 40 minutes).  
225Ac/225/227Ac† radiolabelling reactions were monitored via aluminum backed 
silica thin layer chromatography (TLC) plates (TLC-SG, silica gel 60, F254, MERCK, 
Germany). Developed TLC plates were counted using an AR-2000 imaging scanner 
equipped with PD-10 gas and analysis of RCYs was carried out using WinScan V3_14 
software at least 8 h later to allow for daughter isotopes to decay completely. Radioactivity 
and radionuclidic purity were determined using a High Purity Germanium (HPGe) detector 
(Mirion Technologies (Canberra) Inc.) with Genie 2000 software by measurement of 
gamma emission lines for 213Bi (t1/2 = 45.6 min, 440 KeV, 25.9% abundance) and 221Fr (t1/2 
= 4.9 min, 218 KeV, 11.4% abundance).  
2.5.2. Synthesis Methodology  
 
6-((16-((6-carboxypyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacycloocta decan 
-7-yl)methyl)-4-isothiocyanatopicolinic acid (macropa-NCS, 2.4). Macropa-NCS was 
prepared with slight modifications from previously published procedures17. CSCl2 (50 µL, 
0.7 mmol, 20 Eq) was slowly added to a suspension of Macropa-NH2·4 TFA (2.3; 4-
Amino-6-((16-((6-carboxypyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16- diaza-
cyclooctadecan-7-yl)methyl)picolinic acid) reported in Thiele et al., (30 mg, 29.9 µmol, 1 
Eq) and Na2CO3 (47.5 g, 0.5 mol, 15 Eq) in dry acetone (3 mL). After stirring the reaction 
for 3 hours under argon at room temperature, the solvent was removed under reduced 
pressure. ESI-MS calcd. for [C27H35N5O8S + 2H]+2: 295.61787; found 295.6 [(M+2H)]+2. 



















13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinic acid (VB-02-32, 2.6). N-
N-Diisopropylethylamine (DIPEA; 25 µL, 0.14 mmol, 20 Eq) was added to a solution of 
macropa-NCS (9.8 mg, 16.6 µmol, 2 Eq) and purified CCZ01048 peptide 2.5 (8 mg, 7.1 
µmol, 1 Eq) in dry dimethylformamide (DMF; 0.75 mL) After stirring the reaction 
overnight (12 h) under argon at room temperature, the solvent was removed under reduced 
pressure. The solid was re-dissolved in 23% CH3CN (with 0.1 % TFA) and purified via 
HPLC, using method 2A to yield a colourless oil (300 µg, yield = 2.5%). ESI-MS calcd. 
for [C82H113N22O17S + H]+: 1711.852578; found 1711.8 [M+H]. No NMR was obtained 
for this product. 
2.5.3. 225Ac Sources  
Two sources of Actinium-225 were used within this chapter: A) 225Ac extracted 
from uranium-233 (223U) decay and B) 225Ac produced from irradiated thorium (232Th(p,x) 
225/227Ac†). Actinium-225 acquired from uranium-233 decay (Source A) was obtained from 
Canadian Nuclear Laboratories (CNL) and purified via a DGA resin as described in 
Ramogida et al66., to ensure radionuclide purity. 225/227Ac† acquired from irradiated thorium 
(Source B) was obtained from TRIUMF and the separation of  225/227Ac†  from irradiated 













































a 0.01 M HNO3 solution in final concentrations of either 93.5 or 29.2 kBq/µL. The 
225/227Ac† was received as a 0.01 M HNO3 solution in final concentrations of 50.9 kBq/µL.  
2.5.4. 225Ac Radiolabeling Studies  
Stock solutions (1x 10-3 M) of 2.1, 2.2, and 2.6 were made with ultra-pure deionized 
water. Temperature-dependent and pH-dependent radiolabeling studies were performed by 
the addition of 225/227Ac† or 225Ac (~100 kBq) to a solution containing ligand sock (5 µL; 
or deionized water for negative controls) in either 0.2 M sodium acetate (NaOAc) pH 6.0 
or 0.2 M NaOAc pH 7. The actinium reaction mixtures were gently agitated using a vortex 
mixer and the pH was confirmed to be between 5 - 7 by spotting a portion (1 - 2 µL) of the 
reaction mixture on pH paper. The radiochemical yield (RCY) was analyzed after 30 and/or 
60 minutes at room temperature/elevated temperatures. The iTLC plate system used was: 
Method A - aluminum backed silica with citrate buffer (0.4 M, pH 4.0). Free 225Ac migrates 
with the solvent front (Rf = 1) while 225Ac-ligand complexes will remain at the baseline (Rf 
= 0).  
TLC radio-chromatograms of the radiolabeling (with ligand and control) can be 
found in the Appendix. Measurements were performed in triplicate. 
2.5.5. Human Serum Stability 
The 225Ac-complexes (2.1, 2.2, and 2.6) were prepared using the pre-determined 
ideal radiolabeling conditions as described above. After confirming a radiochemical yield 
>95% by TLC, 180 µL of human serum (3:1 volume, stored at −5°C and thawed at ambient 
temperature) was added to each radiolabeling solution (60 µL). A control was also prepared 
using water instead of ligand. At various times (1 hr to 7 d), small aliquots (3 – 7 µL) were 
spotted on iTLC plates and developed using Method A (vide supra) described above.  
TLC radio-chromatograms of the serum competition assay (with ligand and 
control) can be found in the Appendix. Measurements were performed in triplicates.  
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2.5.6. In Vivo Biodistribution 
Animal experiments were conducted according to the guidelines established by the 
Canadian Council on Animal Care and approved by Animal Ethics Committee of the 
University of British Columbia. B16F10 tumors were inoculated by injection of 1 x 106 
B16F10 cells on the right shoulder of each mouse. A total of eight female C57BL/6J mice 
were used in biodistribution studies for two doses of macropa-CCZ-N-Me-α-CycMSH (n 
= 4 for each dose) once the tumor grew to ~ 8 – 10 mm in diameter.  
Radiotracers were prepared with a high specific activity (>200 kBq/nmol) with the 
predetermined ideal radiolabeling conditions. Purification of the radiotracers was 
performed by loading the radiolabeling reactions onto a pre-conditioned C18 Light 
SepPack to remove free 225Ac3+, collecting the purified peptide in 100% ethanol. The 
radiotracers were further diluted with 0.9% NaCl saline, ensuring the % ethanol 
concentration was <10% by volume in the final formulation to minimize undesired ethanol 
effects seen in mice. Quality control reactions were conducted in parallel and analyzed via 
iTLC to ensure >98% chemical purity by preparing an unlabeled reaction of 225Ac in buffer 
solution. Through an intravenous tail injection, 100 µL of the purified radiolabeling 
reactions was injected into each mouse, recording the time of injection. After 2 hours, the 
mice are sacrificed by CO2 asphyxiation under isoflurane anesthesia. Cardiac puncture was 
promptly performed to recover blood and the organs of interest are harvested, rinsed with 
1 x phosphate buffered saline (PBS), and blotted dry. Organs of interest were weighed and 
measured via a calibrated gamma counter (Packard Cobra II Auto-gamma counter, Perkin 
Elmer, Waltham, MA, USA) using energy windows A) 60 – 120 keV and B) 180 – 260 
keV. Counting was performed immediately after sacrifice and after secular equilibrium 
was met. Radioactivity was decay corrected and normalized to injected dose and expressed 
as the percentage of the injected dose per gram of tissue. No differences were noted 
between the data measured immediately and at equilibrium, or between different energy 
windows; therefore, the biodistributions are reported using the data acquired after 
equilibrium using window A.  
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Chapter 3.  
 
Optimizing pendant donor arms of diaza-18-crown-6 
ligands as chelators for 225Ac 
3.1. Introduction  
A chelator with ideal radiolabeling conditions (vide supra) can be achieved by 
tuning the chelator to the radiometal properties such as coordination number/geometry, 
ligand donor atom preference, ionic radius, and charge72. As mentioned, the highly 
cytotoxic actinium-225 (225Ac3+) is a promising radionuclide for targeted alpha therapy 
with several remarkable clinical trials. With a lack of fundamental knowledge for actinium, 
chelators for actinium-225 are tuned on the basis that it is the largest trivalent actinide with 
a preference for oxygen donors and a coordination number of 8 or 10. 
Initially polyaminocarboxylate and polyaminophosphonate chelates were screened 
for their ability to coordinate 225Ac and form stable complexes in vitro and/or in vivo13,55–
57 (see Figure 3.1). McDevitt et al., compared 225Ac complexation with DTPA, DOTA, 
TETA, DOTPA, TETPA, and DOTMP at 37ºC after 2 hours55. Only DOTA and DOTMP 
were successful in chelation, with 100% and 78% radiochemical yields respectively55. 
When challenged with 25% serum, the 225Ac-DOTMP complex rapidly dissociated while 
the DOTA complex retained >90% intact after 10 days55.  
HEHA was one of the first novel macrocyclic chelators specifically designed for 
225Ac complexation73. With pendent carboxylate arms and polyaza core, HEHA (N6O6) is 
structurally similar to DOTA (N4O4) with a larger macrocyclic core73. Deal et al., 
compared the in vivo stability of HEHA to EDTA, CHX-A”-DTPA, PEPA, and DOTA 
(alongside acetate as a control)73. Quantitative complexation (>95%) was obtained within 
30 minutes at 40ºC for all ligands except PEPA (80%)73. The [225Ac]Ac-DOTA complex 
had significantly decreased uptake in the liver (3.3 % ID/g) and exhibited quicker excretion 
than EDTA, CHX-A”-DTPA, and PEPA. [225Ac]Ac-HEHA had the lowest organ uptake, 
with <0.3% ID/g of radioactivity after 5 days in any organ73. However, the authors 
speculate the overall -3 charge of the complex caused extremely fast excretion, giving the 
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illusion of in vivo stability73. When the in vitro stability of [225Ac]Ac-HEHA-antibody 
conjugates were evaluated, >50% decomposed after 24 h73. While a larger 18-membered 
macrocyclic cavity of HEHA may be better matched to large 225Ac3+ ion, the overall charge 
may not be suitable for in vitro and in vivo stability. DOTA, the only initial chelate that 
provided complexation, in vitro and in vivo stability is considered the current gold standard 
in 225Ac chelation chemistry. 
 
Figure 3.1:  Structures of acyclic and macrocyclic chelators initially investigated 
for actinium-225 
With an intrinsic preference for smaller metal ions and slow complexation, DOTA 
is a mediocre “gold standard” for 225Ac. In the past decade, there have been significant 
efforts in developing 225Ac chelates that form kinetically inert complexes quickly under 
mild temperatures17,18,66,67,72,74. Various macrocyclic and acyclic chelates have been 
proposed for 225Ac3+ chelation; the majority of which outperformed DOTA at ambient 
temperatures17,66,67,72,74. Notably, 5 chelates (CHX-octapa66, py4pa74, noneunpa72, 
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macropa17 and crown67, Figure 3.2) can successfully complex 225Ac3+ (RCY >90%) at 
ambient temperatures with chelator concentrations as low as 10-6 M within one hour. 
Moreover, they have shown favourable in vitro stabilities via a human serum and/or a 
lanthanum competition assay (Table 3.1). However, only crown, macropa, py4pa were 
further investigated via biodistribution studies when conjugated to CycMSH67 (for 
malignant melanoma), RPS-07075 (a PSMA derivative for prostate cancer), and 
Trastuzumab74 (for ovarian cancer) respectively. Perhaps the most interesting fact is that 
these five promising ligands weren’t reported for 225Ac complexation until 2017 – 2021, 
demonstrating much of 225Ac fundamental chelation including predicting chemical 
structures of ligands that complex actinium and exhibit in vitro and in vivo stability is 
unknown.  
 
Figure 3.2: Structures of CHX-octapa, py4pa, noneunpa, crown, and macropa 
chelators discussed 
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Table 3.1: Labeling, in vitro and in vivo data for CHX-octapa, py4pa, noneunpa, 
crown, and macropa chelators discussed 
Chelator Labeling (at 10-6 M) 
In Vitro Stability (% 
intact) In vivo 
La3+ Serum  
CHX-octapa66 ~ 94% RCY at ambient temp within 30 min 
4% 
over 7 d 
96% 
over 7 d N.D* 
py4pa74 ~ 97% RCY at ambient temp within 30 min N.D* 
99% 
over 7 d 
Yes - high tumor 
uptake & moderate 
normal tissue uptake 
noneunpa72 >95% RCY at ambient temp within 10 min N.D* 
90% 
over 7 d N.D* 




over 7 d 
Yes – high tumor 
uptake & moderate/low 
normal tissue 
uptake17,75 




over 5 d 
Yes - high tumor 
uptake & low normal 
tissue uptake 
3.2. Aim of Project 
With the reported success of macropa (N4O6), two novel ligands (3.6 and 3.12) with 
similar characteristics were designed; a diaza-18-crown-6 macrocyclic ligand with 
hydroxypyridinone (HOPO) groups. The HOPO groups offer hard oxygen donors, and 
HOPO derivatives have proven complexation with 89Zr4+, Fe3+, Ga3+, and several actinides. 
Recently, Fiszbein et al., investigated the impact of donor arms on diaza-18-crown-6 
ligands as chelators for 213Bi76; macropa, macroquin-SO3, and macropaquin exhibited 
impressive 213B complexation. Herein, I investigate, 3.6 (macrohopo), 3.12 (macrohopo’), 
3.13 (macroquin-SO3), 3.14 (macropaquin), 3.15 (macropa), and standard DOTA for 225Ac 
complexation. The focus of this chapter is to study the effect of varied rigidity, coordinating 
atoms (N4O6 vs N2O6), and pendant donor arm basicity of diaza-18-crown-6 macrocyclic 
chelators on the ability to complex 225Ac.  
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Figure 3.3:  Structures of chelators DOTA, macropa, macropaquin, macroquin-
SO3, novel macrohopo and macrohopo’ investigated in this chapter 
3.3. Results/ Discussion  
The ligands investigated, 3.6 (macrohopo), 3.12 (macrohopo’), 3.13 (macroquin-
SO3), 3.14 (macropaquin), 3.15 (macropa), and standard DOTA feature varied intrinsic 
characteristics (as seen in Figure 3.3) which can affect the ligands ability to complex 225Ac 
and therefore 225Ac radiolabeling efficiency and complex stability with each ligand should 
be studied.  
42 
3.3.1. Synthesis and characterization 
 
Scheme 3.1: Outlined synthesis of macrohopo (3.6) and macrohopo’ (3.12) from 
same starting material; 6-hydroxypicolinic acid (3.1) 
As illustrated in Scheme 3.1, macrohopo (3.6) and macrohopo’ (3.12) were 
synthesized from the same commercially available starting reagent; 6-hydroxypicolinic 
acid (3.1). Oxidation of 3.1 with peracetic acid and glacial acetic acid formed 3.2 as a pale 
pink solid in good yield (81%). After the first step, 3.6 and 3.12 were synthesized through 
two separate routes as demonstrated in Scheme 3.2 and Scheme 3.3. 
 
Scheme 3.2:  Synthesis of precursors 3.2 – 3.5 and macrohopo (3.6) 
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Protection of 3.2 via benzyl bromide and potassium carbonate in methanol formed 
benzyl protected acid 3.3 as a peach solid in good yield (80%). Subsequent reaction of 3.3 
with N-hydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) 
formed succinimide 3.4, which was purified by silica column chromatography obtaining a 
white crystalline solid in moderate yield (42%). Coupling of 3.4 with commercially 
available 4,13-diaza-18-crown-6-ether produced 3.5. After two silica column purifications, 
3.5 was achieved as a white solid in moderate yields (53%). Deprotection of 3.5 with 1:1 
v:v of concentrated hydrochloric acid and acetic acid formed the final ligand 3.6 which was 
purified via preparative high performance liquid chromatography (HPLC) using method 
3A, resulting in a good yield of 56%.  
 
Scheme 3.3:  Synthesis of precursors 3.7 – 3.11 and macrohopo’ (3.12) 
Products 3.2 – 3.10 have been previously reported and were synthesized following 
established procedures77. The addition of thionyl chloride (SOCl2) in methanol produced 
methyl ester 3.7 in quantitative yields (>99%). Subsequent protection with allyl bromide 
and potassium carbonate in acetonitrile (CH3CN) yielded 3.8 as a pale brown/orange solid 
in good yield (91%). Reduction of the protected methyl ester 3.8 with sodium borohydride 
in methanol formed the protected alcohol 3.9 in moderate yields (63%). Halogenation of 
3.9 with thionyl chloride in dry dichloromethane (DCM) produced 3.10 in excellent yields 
(97%). Conjugation of 3.10 with commercially available 4,13-diaza-18-crown-6-ether 
produced 3.11. Products 3.7 to 3.10 were easily worked up with minimal purification. 
While 3.11 required two separate silica column purifications to produce a brown solid 
(yield = 85%). Subsequent deprotection of 3.11 with boron trichloride (1M in dry DCM) 
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formed 3.12 as a brown solid. 3.12 was purified via preparative high performance liquid 
chromatography (HPLC) using method 3A, resulting in a moderate yield of 56%.  
Intermediates 3.2 – 3.5 and 3.7 – 3.11 were fully characterized using high resolution 
electrospray ionization mass spectrometry (HR-ESI-MS) and NMR (1H, 13C, COSY, 
HSQC, and HMBC). Previously reported compounds (3.2, 3.7 – 3.10) were in good 
agreement with reported NMR spectra & mass spectrometry values. Final compounds 3.6 
and 3.12 were successfully complexed with lanthanum perchlorate (La(ClO4)3• 6H2O), and 
their metal complexes were fully characterized using HR-ESI-MS and NMR (1H, 13C, 
COSY, HSQC, and HMBC).  
The 1H NMR spectra at 25 °C in dimethylsulfoxide-d6 (DMSO-d6) of 3.6 shows three 
distinct peaks at 7.41, 6.54, and 6.22 ppm corresponding to the HOPO pendant arms and 
an unresolvable multiplet at 3.55 ppm corresponding to the macrocyclic core (Figure 3.4). 
Variable temperature (VT) NMR experiments from 10 to 40°C in D2O were performed, 
but there were no spectral changes. Upon complexation with La3+, studying the 1H NMR 
spectra for the pendant donors arm region shows one major isomer with one (or more) 
isomers present in solution (Figure 3.4). VT NMR (30 to 50°C) of [La(macrohopo)][ClO4] 
showed no spectral changes (see Appendix Figure A30).  
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Figure 3.4: 1H NMR spectra at 25 °C in DMSO-d6 of 3.6 (top) and 
[La(macrohopo)][ClO4] (bottom) 
The 1H NMR spectra at 25 °C in DMSO-d6 of 3.12 indicates a C2 symmetry, as 
reflected by chemical equivalents of the pendant donor arms (see Figure 3.5). Upon 
complexation with La3+, the 1H NMR spectrum (Figure 3.5 and Figure 3.6) shows distinct 
coupling patterns in the pendant donor arm region, which in conjunction with 13C-, COSY-
, HMBC-, and HSQC- NMR spectra was utilized to determine that two isomers are present 
in solution. Correlation between I) a1, b1, and c1 and II) a2, b2, and c2 were evident on the 
COSY with no correlation between a1 and a2, b1 and b2, and c1 and c3 indicating two 
separate isomers (see Appendix Figure A28). The relative chemical equivalence between 
the asymmetric (a2, b2, and c2) and the symmetric (a1, b1, and c1) pendant donor arms 
indicate a 1:1 ratio is present (Figure 3.6). Variable temperature (VT) NMR was 
performed, increasing the ratio of the asymmetric isomer (60:40) as temperature increased 
(see Appendix Figure A31).   
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Figure 3.5:  1H NMR spectra at 25 °C in DMSO-d6 of [La(macrohopo’)][ClO4] 
(top) and 3.12 (bottom) 
 
 
Figure 3.6:  1H NMR spectra at 25 °C in DMSO-d6 of [La(macrohopo’)][ClO4] 
(bottom) and 3.12 (top) illustrating a 1:1 asymmetric:symmetric ratio 
in solution; red – asymmetric, blue – symmetric  
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Chelates macropa (3.15), macropaquin (3.14), and macroquin-SO3 (3.13) were 
synthesized and characterized by Fiszbein, D at Cornell University (Wilson Group) based 
on established procedures17,78,79. Lanthanum complexation of macropa has been previously 
reported by Thiele et al., wherein full characterization (including NMR, IR, HPLC, x-ray 
crystallography, and UV-vis spectroscopy) was performed17. Lanthanum complexation of 
macropaquin (3.14) and macroquin-SO3 (3.13) was not performed.  
3.3.2. UV-Vis 
In situ complexation of 3.6 and 3.12 with lanthanum (La(ClO4)3•6H2O) was 
observed using UV-Vis. A solution of lanthanum perchlorate was added to either 3.6 or 
3.12 in 0.1 M KCl/0.1 M HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
buffer solution (pH = 7.4) at 0.5 equivalents increments until excess metal (≥2 Eq) was 
present. Formation of [La(macrohopo)][ClO4] occurred when 1.0 equivalents of lanthanum 
was added to the ligand solution, indicated by the 𝜆9:; shift from 323 nm to 314 nm 
(Figure 3.7). As excess metal was added, the 𝜆9:; at 314 nm did not significantly shift in 
absorbance or wavelength, indicating a 1:1 metal to chelate (La:macrohopo) ratio. 
Complexation of 3.12 occurred when 0.5 equivalents of lanthanum was added to the ligand 
solution, indicated by the 𝜆9:; shift from 318 nm to 309 nm (Figure 3.7). Similarly to 3.6, 
a 1:1 metal to chelate ratio is demonstrated.  
 
Figure 3.7: UV-Vis spectra of in situ lanthanum complexation with novel 
chelators 3.6 (left) and 3.12 (right) 
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A possible explanation for [La(macrohopo’)][ClO4] formation occurring at 0.5 
metal Eq instead of 1 equivalent is the inability to get elemental analysis (EA) of 
macrohopo’. Precise molecular weights of these ligands are crucial when dealing with 10-5 
M final ligand concentrations. Unaccounted TFA, acetonitrile, and/or water molecules 
present in the final compound, can significantly vary the Eq of ligand present ultimately 
impacting the amount of metal required for complexation.  
3.3.3. Initial Radiolabeling 
Determination of ideal 225Ac3+ radiolabeling conditions at final ligand 
concentrations of 10-3 or 10-4 M (buffer, pH, and reaction time) were performed during 
initial radiolabeling experiments. Subsequent concentration dependence studies were 
executed using the ideal radiolabeling conditions and the results are compiled in Figure 
3.8. Not surprisingly, gold standard DOTA required heating at 80 °C for 1 hr to obtain 
quantitative labelling at 10-3 M. DOTA was able to maintain quantitative labeling at 10-4 
M; however, as ligand concentrations decreased to 10-5, 10-6, and 10-7 M, the radiochemical 
yield decreased to 37.5 ± 7.9, 4.5 ± 0.8 and <1% respectively. Macropa results were 
comparable to previous impressive findings, with quantitative labeling achieved for 10-6 M 
final ligand concentrations at ambient temperatures17. Impressively, within 5 minutes 
macropaquin can achieve >95% RCY for 10-5 M at ambient temperatures (pH 5.5). For   
10-6 M, macropaquin exhibits slower kinetics with 26.0% RCY at 5 minutes and 92.6% 
RCY after 1 hour. With a RCY >90%, macropaquin becomes the 6th reported ligand that 
can obtain quantitative 225Ac labeling at ambient temperatures within 1 hour for 10-6 M. 
Conversely, macroquin-SO3 was able to achieve quantitative labeling at 10-4 and 10-5 M, 
but dropped to 47.6 ± 47.1% RCY for 10-6 M at ambient temperatures (pH 7.0). At even 
10-3 M final ligand concentration, macrohopo was unable to complex 225Ac at ambient 
temperatures in a variety of buffers (0.1 M HEPES, NaOAc, NH4OAc, MeOH, and EtOH) 
and pHs (between 5.5 – 10.0) after 1 hr. Heating the reaction to 80 °C and/or allowing it to 
proceed for longer (2 hr) did not facilitate 225Ac complexation. Due to limited radionuclide 
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supply, macrohopo’ was not investigated for 225Ac complexation at this time, but will be 
performed in future.   
 
Figure 3.8:  Radiochemical yields (RCY, %) for 225Ac3+ radiolabeling reactions of 
DOTA (pH 5.5, 85 °C, 1h), macropa (pH 6, RT, 1h), macropaquin (pH 
5.5, RT, 1h), macroquin-SO3 (pH 6, RT, 1h) and macrohopo (pH 5 – 11, 
85 °C, 1h) 
The ligands investigated, 3.6 (macrohopo), 3.13 (macroquin-SO3), 3.14 
(macropaquin), and 3.15 (macropa), feature varied intrinsic characteristics which can affect 
the ligands ability to complex 225Ac. As protons compete with metal ions for binding sites 
on ligands, ligand basicity is an important factor for a ligand’s metal affinity80. Thiele et 
al., determined the protonation constants (Ka) for macropa, macropaquin, and macroquin-
SO380 (Appendix Table A1). The replacement of picolinate arms on macropa by 8-
hydroxyquinoline groups decreases the basicity of the nitrogen atoms of the macrocyclic 
core80, a trend seen with various other chelators80–84. While the SO3 electron withdrawing 
groups of macroquin-SO3 produce more acidic phenols (log Ka1 = 9.34 and log Ka2 = 9.43) 
when compared to macropaquin (log Ka1 = 10.33), macropaquin and macroquin-SO3 do 
not exist fully deprotonated in solution below pH of 8.080. At physiological pH (7.4), 43% 
of macropa is fully deprotonated whereas, the monoprotonated species of macropaquin 



















Macropa DOTA Macroquin-SO3 Macropaquin Macrohopo
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increased overall basicity of macropaquin may explain the slower kinetics at 10-6M 
chelator concentrations when compared to macropa. The 1,2-hydroxypyridinone groups in 
3.6 and 3.12 have a reported log ka value of 5.8785, and the secondary amines of diaza-18-
crown-6 macrocycles typically range from 6 – 976,79,80,86. Theoretically, 3.6 and 3.12 should 
exhibit slightly lower/comparable overall basicity to macropaquin and macroquin-SO3. 
However, experimental determination of the protonation constants for 3.6 and 3.12, were 
not performed at this time.  
The hydroxypyridinone groups on 3.6 and 3.12 offer hard oxygen donors, 
appropriate for 225Ac complexation. With four oxygens and two nitrogens on the 
macrocyclic backbone, the hydroxypyridinone pendent arms facilitate a 10 coordination 
species (N2O8). The inability of 3.6 to complex actinium may be associated with pendant 
donor arms rigidity, a result of the carbonyl group on the pendant donor arms. If the HOPO 
pendant donor arms on 3.12 don’t participate in the coordination, poor 225Ac complexation 
of the diaza-18-crown-6 macrocycle can be expected. 
Interestingly, all chelators with superior 225Ac complexation (CHX-octapa66, 
py4pa74, noneunpa72, macropa17 and crown67 and macropaquin) contain ≥1 
aminocarboxylate group with a large core that can accommodate the large 225Ac actinide 
and overall +1 or -1 charge. Yet, they vary in flexibility (macrocyclic vs acyclic), 
coordination number (CN = 8, 10, and/or 11), coordinating atoms (N4O4, N7O4, and N4O6), 
and pendant donor arm basicity.  
3.4. Conclusion & Future Work 
In chapter 3, two novel HOPO ligands (3.6 and 3.12) were synthesized and 
characterized via NMR, HPLC, MS, and UV-Vis. The ability to complex lanthanum 
(225Ac3+ closest non-radioactive surrogate) was examined, wherein both ligands illustrated 
complexation with multiple isomers present. A 1:1 metal:chelate ratio for the lanthanum 
complexes was studied via UV-Vis as a shift in 𝜆9:; from 323 nm to 314 nm for 3.6 and 
318 nm to 309 nm for 3.12. Initial radiolabeling of macropa and DOTA were consistent 
with reported data, while macropaquin shows great promise. Conversely, 3.6 was unable 
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to complex 225Ac under any conditions and due to limited radionuclide supply, 3.12 was 
not investigated.  
Future work for this project is intensive, including both non-radioactive and 
radioactive work. Specifically, fundamental characterization of 3.6 and 3.12 such as pKa 
determination, thermodynamic affinity for La3+, and DFT calculations are essential. When 
225Ac becomes available, 3.12 should be investigated for 225Ac complexation, utilizing the 
same condition as 3.6 radiolabeling. By directly comparing 3.6 and 3.12, the effect of 
pendant donor arm flexibility can be investigated. Furthermore, with promising initial 
radiolabeling for macropaquin, its kinetic inertness should be evaluated in vitro via a 
human serum assay. As two novel ligands, 3.6 and 3.12 should be screened for 
radionuclides with similar intrinsic properties as 225Ac3+. Particularly with 89Zr4+, a hard, 
oxophilic cation with proven complexation and excellent in vitro stability for an 
octadentate acyclic HOPO chelator87.  
3.5. Experimental   
3.5.1. Materials and Methods  
All solvents and reagents were purchased from commercial suppliers (TCI 
America, Fisher Scientific, Macrocyclic, and Sigma Aldrich). Solvents noted as “dry” were 
obtained following storage over 3 Å molecular sieves. 1H and 13C NMR spectra were 
referenced to the residual solvent peak and recorded at 25oC (unless noted otherwise) on 
Bruker AV400, AV500, or AV600 instruments. Deionized water (>18 MΩ cm) was used 
via Millipore-Direct (Milli-Q IQ 7000) purification systems. High-resolution electrospray-
ionization mass spectrometry (HR-ESI-MS) was performed on an Agilent 6210 time-of-
flight instrument (TOF). Semi-preparative and preparative HPLC were used for the 
purification of non-radioactive compounds. Semi-preparative purification was performed 
on an Agilent 1100 series consisting of a G1311A Quaternary Pump, G2260A autosampler, 
and G1315B variable wavelength absorbance detector. Semi-preparative purification was 
performed with a Kinetex semi-preparative C18 column, 5 µm, 100 Å, 150 x 10.0 mm at a 
flow rate of 3.0 mL/min unless otherwise noted. Preparative purification was performed on 
an Agilent 1100 series consisting of a G1361A Quaternary Pump, G2260A autosampler, 
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and G1365D variable wavelength absorbance detector. Preparative purification was 
performed with a Gemini-NX preparative C18 column, 5 µm, 110 Å, 100 x 30.0 mm at a 
flow rate of 15.0 mL/min unless otherwise noted. Gradient HPLC methods utilized a binary 
mobile phase that contained H2O with 0.1 % TFA (A) and CH3CN with 0.1 % TFA (B). 
HPLC methods: 
• 3A: 2 – 50% B (0 – 20 min), 50 – 100% B (20 – 22 min), 100% B (22 – 24 
min), 100 – 2% B (24 – 26 min), 2% B (26 – 30 min).  
• 3B: 2 – 50% B (0 – 10 min), 50 – 100% B (10 – 12 min), 100 – 10% B (12 – 
14 min), 10% B (14 – 15 min). 
• 3C: 5 – 15% B (0 – 20 min), 15 – 100% B (20 – 24 min), 100% B (24 – 26 
min), 100 – 2% B (26 – 28 min), 2% B (28 – 30 min). 
3.5.2. Synthesis Methodology 
 
1-hydroxy-6-oxo-1,6-dihydropyridine-2-carboxylic acid (1,2-HOPO-Acid, 3.2). 
Compound 3.2 was prepared as previously reported77. Peracetic acid (15 mL) was carefully 
added dropwise to a white suspension of 6-hydroxypicolinic acid (5.0 g, 36 mmol, 1 Eq) 
in glacial acetic acid (30 mL) while stirring. The flask was heated to 80°C for 12 hrs before 
the solid was filtered and washed with diethyl ether to yield 3.2 as a cream solid (4.50 g, 
yield = 80.6%). The 1H NMR data for the product was in good agreement with those 
previously reported in the literature; 1H NMR (400 MHz, DMSO-d6) δ 7.44 (dd, J = 9.0, 
7.0, Ar-H, 1H), 6.71 (dd, J = 9.0, 1.7, Ar-H, 1H), 6.66 (dd, J = 7.0, 1.7, Ar-H, 1H). 13C 
NMR (101 MHz, DMSO-d6), δ 161.9 (COOH), 157.1 (C=O), 138.8 (CCOOH), 136.5 (Ar-
C), 120.3 (Ar-C), 106.3 (Ar-C). HR-ESI-HRMS calcd. for [C6H5NO4 + H]+: 156.02913; 









1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2-carboxylic acid (1,2-HOPO-OBn-Acid, 3.3). 
Benzyl bromide (1.10 ml, 9.3 mmol, 1.2 Eq) and potassium carbonate (2.1 g, 15.5 mmol, 
2 Eq) were added to a white suspension of 1,2-HOPO Acid 3.2 (1.2 g, 7.7 mmol, 1 Eq) in 
methanol (30 mL). The white suspension was refluxed at 75°C overnight (16 h), producing 
a dark green transparent solution after ~10 minutes followed by a brown solution with a 
grey precipitate after 16 h. The solution was filtered via a Büchner funnel, the solvent was 
removed under reduced pressure, and the resulting brown residue was dissolved in water. 
The addition of concentrated HCl dropwise formed a white precipitate which was filtered, 
washed with water, and dried under vacuum to yield 3.3 as a peach solid (1.52 g, yield = 
80.1%). 1H NMR (400 MHz, DMSO-d6) δ 7.49 (m, Ar-H, 3H), 7.44 (m, Ar-H, 3H), 6.74 
(dd, J = 9.3, 1.7, Ar-H, 1H), 6.56 (dd, J = 6.8. 1.7, Ar-H, 1H), 5.28 (s, OCH2C6H5, 2H). 
13C NMR (101 MHz, DMSO-d6), δ 161.6 (COOH), 157.6 (C=O), 140.5 (CCOOH), 138.6 
(Ar-C), 133.8 (OCH2CC5H5), 129.6 (Ar-C), 129.0 (Ar-C), 128.5 (Ar-C), 124.0 (Ar-C), 
105.9 (Ar-C), 77.9 (OCH2C6H5). HR-ESI-MS calcd. for [C13H11NO4 + H]+: 246.07608; 




HOPO-OBn-Succ, 3.4). N-hydroxysuccinimide (420 mg, 3.7 mmol, 1.2 Eq) and 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide (704 mg, 3.7 mmol, 1.2 Eq) were added to a 
solution of 3.3 (750 mg, 3.1 mmol, 1 Eq) in dry CH2Cl2 (70 mL). After stirring the reaction 















brine (50 mL), the organic layer was dried over Na2SO4, filtered, and the solvent was 
removed under reduced pressure. The crude product was purified by silica column 
chromatography (using CH2Cl2:CH3CN 5:1 as eluent) to obtain a white crystalline solid 
(439 mg, yield = 41.9 %). 1H NMR (400 MHz, CDCl3), δ 7.56 (m, Ar-H, 2H), 7.36 (m, Ar-
H, 4H), 6.95 (m, Ar-H, 2H), 5.38 (s, OCH2C6H5, 2H), 2.92 (s, O=CCH2CH2C=O, 4H). 13C 
NMR (101 MHz, CDCl3), δ 168.5 (O=CCH2CH2C=O), 158.5 (C=OON), 155.2 (C=O), 
136.8 (Ar-C), 133.3 (Ar-C), 130.4 (Ar-C), 129.4 (Ar-C), 129.1 (Ar-C), 128.7 (Ar-C), 111.7 
(Ar-C), 79.0 (OCH2C6H5), 25.8 (O=CCH2CH2C=O). HR-ESI-MS calcd. for [C17H14N2O6 





ether (150 mg, 0.6 mmol, 1 Eq) was added to a solution of 3.4 (489 mg, 1.4 mmol, 2.5 Eq) 
in dry CH2Cl2 (8 mL). Triethylamine (TEA) was added at RT and the reaction was left 
stirring under argon for 24 hrs. The solvent was removed under reduced pressure yielding 
a brown oil. The residual was dissolved in CH2Cl2 (50 mL), washed with water and brine 
(2 x 50 mL), and the organic layer was dried over sodium sulfate. The solvent was removed 
under reduced pressure to yield a brown transparent solution. The crude product was 
purified via silica column chromatography (using CH2Cl2:MeOH 9:1 as the eluent) 
followed by another silica column (using CHCl3:MeOH 9:1 as the eluent) to yield a white 
solid (217 mg, yield = 52.9%). 1H NMR (600 MHz, CDCl3), δ 7.53 (m, Ar-H, 4H), 7.35 
(m, Ar-H, 8H), 6.71 (m, Ar-H, 2H), 6.07 (m, Ar-H, 2H), 5.65 (m, OCH2C6H5, 2H), 5.02 
(m, OCH2C6H5, 2H), 3.47 (m, C12N2O4H24, 24H). 13C NMR (151 MHz, CDCl3), δ 162.3 













C), 130.5 (Ar-C), 130.5 (Ar-C), 129.4 (Ar-C), 129.4 (Ar-C), 128.6 (Ar-C), 123.1 (Ar-C), 
102.9 (Ar-C), 102.8 (Ar-C), 79.4 (OCH2C6H5), 70.6 (C12N2O4H24), 70.5 (C12N2O4H24), 
70.4 (C12N2O4H24), 70.4 (C12N2O4H24), 70.2 (C12N2O4H24), 69.8 (C12N2O4H24), 69.7 
(C12N2O4H24), 69.5 (C12N2O4H24), 69.4 (C12N2O4H24), 69.3 (C12N2O4H24), 69.2 
(C12N2O4H24), 69.0 (C12N2O4H24), 69.0 (C12N2O4H24), 49.5 (C12N2O4H24), 49.5 
(C12N2O4H24), 49.4 (C12N2O4H24), 46.3 (C12N2O4H24), 46.2 (C12N2O4H24), 46.2 
(C12N2O4H24), 46.1 (C12N2O4H24). HR-ESI-MS calcd. for [C38H44N4O + H]+ : 717.3130; 




hydroxypyridin-2(1H)-one) (macrohopo, 3.6). Concentrated hydrochloric acid (3.2 mL) 
and glacial acetic acid (3.2 mL) (1:1v/v) was added to 1,2-HOPO-OBn-Crown 3.5 (100 
mg, 0.14 mmol). After heating the reaction at 50°C for 3d, the solvent was removed under 
reduced pressure. The brown crude residue was dissolved in H2O and purified via HPLC, 
using method 3A (preparative) or 3B (semipreparative) to yield a colourless oil (34.5 mg, 
yield = 56.1%). 1H NMR (600 MHz, D2O) δ 7.48 (td, J = 9.2, 7.0 Hz, Ar-H, 2H), 6.66 (m, 
Ar-H, 2H), 6.45 (ddd, J = 6.6, 4.6, 1.7 Hz, Ar-H, 2H), 3.76 – 3.38 (m, C12N2O4H24, 24H). 
13C NMR (151 MHz, D2O) δ 163.5, 163.5, 160.2, 140.6, 140.5, 139.8, 139.8, 120.2, 117.1, 
115.2, 106.4, 69.9, 69.9, 69.7, 69.7, 68.6, 68.5, 67.9, 67.8, 49.6, 49.6, 46.4, 46.4. HR-ESI-
MS calcd. for [C24H32N4O10 + H]+: 537.2191; found 537.2186 [M+H]+. Elemental 
Analysis: calcd. (found) for C24H32N4O10·1 TFA·2H2O: C, 45.48 (45.57); H 5.43 (5.11); N 















Methyl 1-hydroxy-6-oxo-1,6-dihydropyridine-2-carboxylate, (1,2-HOPO-methylester, 
3.7). Compound 3.7 was prepared as previously reported77. Thionyl chloride (5.8 mL, 78.0 
mmol, 4 Eq) was added dropwise to a white suspension of 3.2 (3.0 g, 19.3 mmol, 1 Eq) in 
dry methanol (38.5 mL) at 0°C. After the mixture was refluxed for 4 hours at 85°C, the 
orange solution was cooled to room temperature. The solvent was removed under reduced 
pressure yielding 3.7 as an orange solid (3.25 g, yield >99 %). The 1H NMR data for the 
product was in good agreement with those previously reported in the literature. 1H NMR 
(400 MHz, DMSO-d6), 7.44 (dd, J = 9.2, 6.8 Hz, Ar-H, 1H), 6.69 (dd, J = 9.1, 1.6 Hz, Ar-
H, 1H), 6.52 (dd, J = 6.9, 1.6 Hz, Ar-H, 1H), 3.87 (s, CO2CH3, 3H). 13C NMR (101 MHz, 
DMSO-d6) δ 161.3 (CO2CH3), 158.0 (C=O), 138.7 (Ar-C), 137.8 (Ar-C), 122.5 (Ar-C), 





methylester, 3.8). Compound 3.8 was prepared as previously reported77. Allyl bromide (4.1 
mL, 47.80, 2.5 Eq) and potassium carbonate (6.60 g, 47.80 mmol, 2.5 Eq) were added to 
an orange suspension of 3.7 (3.24 g, 19.17 mmol, 1 Eq) in acetonitrile (42 mL). The flask 
was refluxed at 90°C, for 4 hrs before the mixture was filtered and the solvent was removed 
under reduced pressure. The residue was dissolved in toluene and the solvent was removed 
under reduced pressure to yield 3.8 as a pale orange solid (3.65 g, yield = 91.1%). The 1H 
NMR data for the product was in good agreement with those previously reported in the 
literature. 1H NMR (500 MHz, CDCl3) δ 7.30 (m, Ar-H, 1H), 6.80 (dd, J = 9.2, 1.6 Hz, Ar-










OCH2CHCH2, 2H), 4.90 (m, OCH2CHCH2, 2H), 3.93 (s, CH3, 3H). 13C NMR (126 MHz, 
CDCl3) δ 160.6 (CO2CH3), 158.9 (C=O), 138.7 (quart. C) 137.2 (Ar-C), 130.6 
(OCH2CHCH2), 126.0 (Ar-C), 122.0 (OCH2CHCH2), 108.0 (Ar-C), 78.1 (OCH2CHCH2), 




1-(allyloxy)-6-(hydroxymethyl)pyridin-2(1H)-one (1,2-HOPO-allyl-hydroxide, 3.9). 
Compound 3.9 was prepared as previously reported77.  Sodium borohydride (4.09 g, 108.3 
mmol, 7 Eq) was added to a solution of 3.8 (3.24 g, 15.5 mmol, 1 Eq) in tetrahydrofuran 
(42 mL) at room temperature. The flask was refluxed at 80°C for 15 minutes before the 
dropwise addition of methanol (2.4 mL) over 2 hours. The solution was then cooled to 0°C 
and quenched by the addition of ammonium chloride (4.2 mL). After stirring for an 
additional 15 minutes, the solvents were removed under reduced pressure. The residue was 
extracted with CH2Cl2 until the aqueous layer was a colourless transparent solution. The 
combined organic layers were dried with sodium sulfate and the solvent was removed 
under reduced pressure to yield 3.9 as an off white solid (1.49 g, yield = 62.5 %). The 1H 
NMR data for the product was in good agreement with those previously reported in the 
literature. 1H NMR (500 MHz, CDCl3) δ 7.29 (dd, J = 9.2, 6.9 Hz, Ar-H, 1H), 6.57 (dd, J 
= 9.1, 1.7 Hz, Ar-H, 1H), 6.27 (dd, J = 6.9, 1.9, Ar-H, 1H), 6.04 (m, OCH2CHCH2, 1H), 
5.41 (m, OCH2CHCH2, 2H), 4.81 (d, J = 6.7, OCH2CHCH2, 2H), 4.68 (s, CH2OH, 2H), 
2.95 (s, CH2OH, 1H). 13C NMR (126 MHz, CDCl3) δ 159.5 (C=O), 148.4 (Ar-C), 138.5 
(Ar-C), 130.2 (OCH2CHCH2), 122.6 (OCH2CHCH2), 120.7 (Ar-C), 103.6 (Ar-C), 77.2 








1-(allyloxy)-6-(chloromethyl)pyridin-2(1H)-one (1,2-HOPO-allyl-chloride, 3.10). 
Compound 3.10 was prepared as previously reported77. Thionyl chloride (3.6 mL, 49.6 
mmol, 6 Eq) was added dropwise to a yellow solution of 3.9 (1.5 g, 8.2 mmol, 1 Eq) in dry 
CH2Cl2 (36 mL) at room temperature. After refluxing at 50°C for 6 hours, the solution was 
then cooled to 0°C and quenched with the addition of ice water (30 mL). After stirring the 
biphasic reaction mixture for an additional 30 minutes, the phases were separated, and the 
aqueous phase was further extracted with CH2Cl2 (3 x 40 mL). The combined organic 
phases were dried with sodium sulfate and the solvent was removed under reduced pressure 
to yield 3.10 as a brown crystalline solid (1.59 g, yield = 97.0%). The 1H NMR data for the 
product was in good agreement with those previously reported in the literature. 1H NMR 
(500 MHz, CDCl3) δ 7.27 (d, J = 7.0 Hz, Ar-H, 1H), 6.66 (dd, J = 9.3, 1.7 Hz, Ar-H, 1H), 
6.25 (dd, J = 6.8, 1.7 Hz, Ar-H, 1H), 6.11 (m, OCH2CHCH2, 1H), 5.45 (m, OCH2CHCH2, 
2H), 4.93 (d, J = 6.6 Hz, OCH2CHCH2, 2H), 4.57 (s, CH2Cl, 2H). 13C NMR (126 MHz, 
CDCl3) δ 159.2 (C=O), 144.3 (Ar-C), 137.8 (Ar-C), 130.3 (OCH2CHCH2), 123.0 (Ar-C), 
122.4 (OCH2CHCH2), 106.3 (Ar-C), 77.4 (OCH2CHCH2), 39.4 (CH2Cl). HR-ESI-MS 




(allyloxy)pyridin-2(1H)-one) (1,2-HOPO-allyl-crown, 3.11). 4,13-Diaza-18-crown-6-
ether (287 mg, 1.1 mmol, 1 Eq) and potassium carbonate (605 mg, 4.4 mmol, 4 Eq) were 
added to a solution of 3.10 (547 mg, 2.7 mmol, 2.5 Eq) in dry acetonitrile (7.5 mL). The 
















suspension was extract with CH2Cl2 (10 mL) and the combined organic fractions water 
dried with sodium sulfate. The solvent was removed under reduced pressure to yield a 
brown oil. The crude product was purified via silica column chromatography (using a 
gradient of CH2Cl2:MeOH 99:1 to CH2Cl2:MeOH 90:10 as the eluent). The solvent was 
removed under reduced pressure to yield 3.11 as a brown solid (550 mg, yield = 85.3%). 
1H NMR (MeOD, 600 MHz), δ7.47 (dd, J = 9.1, 7.0 Hz, Ar-H, 2H), 6.67 (dd, J = 7.01, 1.7 
Hz, Ar-H, 2H), 6.55 (dd, J = 9.1, 1.8 Hz, Ar-H, 2H), 6.14 (m, OCH2CHCH2, 2H) 5.47 (m, 
OCH2CHCH2, 2H), 5.38 (m, OCH2CHCH2, 2H), 4.82 (m, OCH2CHCH2, 4H), 3.89 (s, 
NCH2, 4H), 3.63 (t, J = 5.5 Hz, NCH2CH2O, 8H), 3.57 (s, OCH2CH2O, 8H), 2.89 (t, J = 
5.5 Hz, NCH2CH2O, 8H). 13C NMR (MeOD, 151 MHz), δ 162.1 (C=O), 150.4 (Ar-C), 
140.8 (Ar-C), 132.2 (OCH2CHCH2), 122.4 (OCH2CHCH2), 120.0 (Ar-C), 108.2(Ar-C), 
78.2 (OCH2CHCH2), 71.8 (OCH2CH2O), 71.0 (NCH2CH2O), 55.7 (NCH2 or NCH2CH2O), 
55.6 (NCH2 or NCH2CH2O). HR-ESI-MS calcd. for [C30H44N4O8 +H]+: 589.3232; found 




hydroxypyridin-2(1H)-one) (macrohopo’, 3.12). Boron trichloride (1M in CH2Cl2, 1.8 
mL, 1.8 mmol, 7 Eq) was added dropwise to a brown solution of 3.11 (142.4 mg, 0.3 mmol, 
1 Eq) in dry CH2Cl2 (2 mL) at 0°C under argon. The solution was warmed to room 
temperature and allowed to stir overnight under argon. The solid precipitate was filtered 
and washed with CH2Cl2 and air dried to yield a yellow/white solid. The yellow solid was 
dissolved in H2O and purified via HPLC, using method 3A (preparative) or 3C 
(semipreparative) to yield a colourless oil (74.2 mg, yield = 56.2%). The 1H NMR data for 
the product is as followed: 1H NMR (600 MHz, DMSO) δ 7.40 (m, Ar-C, 2H), 6.62 (d, J 
= 9.1, Ar-C, 2H), 6.49 (d, J = 7.0, Ar-C, 2H), 4.49 (s, NCH2, 4H), 3.76 (t, J = 5.0 Hz, 
NCH2CH2O, 8H), 3.55 (s, OCH2CH2O, 8H), 3.37 (t, NCH2CH2O, 8H).13C NMR (151 










69.6 (OCH2CH2O), 65.0 (NCH2CH2O), 53.7 (NCH2CH2O), 53.2 (NCH2). HR-ESI-MS 
calcd. for [C24H36N4O8 + H]+: 509.2606; found 509.2591 [M+H]+. 
 
3.5.3. Non-radioactive metal complexation  
 
[La(macrohopo)][ClO4]. A solution of La(ClO4)3• 6H2O (17 mg, 31.3 µmol, 1.1 
Eq) in CH3OH (0.5 mL) was added to a solution of macrohopo (15 mg, 28 µmol, 1 Eq) in 
in CH3OH (0.5 mL) at room temperature upon which time a precipitate formed 
immediately. The white suspension was centrifuged (2 min, 14,800 rpm), removing the 
supernatant and washing the pelleted with CH3OH (2 x 0.5 mL) followed by (C2H5)2O (2 
x 0.5 mL). The pellet was then air-dried on filter paper to give the complex as a white solid 
(17.4 mg, yield = 77.9%). The 1H NMR data (600 MHz, DMSO) δ 7.31 (m, Ar-H, 2H), 
6.48 (m, Ar-H, 4H), 3.50 (m, C12N2O4H24, 33H). 13C NMR (151 MHz, DMSO) δ 163.8, 
162.4, 162.2, 142.8, 133.1 113.7, 106.7, 70.9, 70.4, 69.2, 68.5, 49.1, 47.5, 44.5, 40.5. ESI-
MS calcd. for [C24H30N4O10La]+: 673.1025; found 673.1 [M]+ 
 
[La(macrohopo’)][ClO4]. A solution of La(ClO4)3• 6H2O (24 mg, 43.3 µmol, 1.1 
Eq) in CH3OH (0.5 mL) was added to a solution of macrohopo’ (20 mg, 39.3 µmol, 1Eq) 
and triethylamine (22 µL, 0.2 mmol, 4 Eq) in CH3OH (0.5 mL) at room temperature. A 
precipitate formed immediately. The white suspension was centrifuged (2 min, 14,800 
rpm), removing the supernatant and washing the pelleted with CH3OH (2 x 0.5 mL) 
followed by (C2H5)2O (2 x 0.5 mL). The pellet was then air-dried on filter paper to give 





























DMSO) δ 7.27 (m, Ar-H, 1H), 7.16 (m, Ar-H, 2H), 6.76 (m, Ar-H, 1H), 6.54 (m, Ar-H, 
2H), 6.43 (m, Ar-H, 1H), 6.30 (m, Ar-H, 1H), 3.90 (s, 2H), 1.83 (s, 2H), 3.56 (m), 3.51 (s), 
3.47 (m), 3.16 (d, 1H), 2.90 (s, 5H), 2.78 (t, 4H), 2.67 (s, 3H). 13C NMR (151 MHz, DMSO) 
δ 162.4, 162.7, 147.9, 147.5, 147.2, 131.1, 132.1, 110.3, 110.1, 107.2, 107.1, 106.8, 105.6, 
99.5, 70.6, 69.9, 65.4, 54.9, 54.4, 53.8, 46.1 (extrapolated from 13C, HSQC, and HMBC). 
HR-ESI-MS calcd. for [C24H34N4O8La]+: 645.1440; found 645.1414 [M]+. 
 
3.5.4. UV-Vis 
Stock solutions of La(ClO4)3• 6H2O (1 x 10-3 M), 3.6 (1 x 10-3 M), and 3.12 (1 x 
10-3 M) were prepared in MQ H2O. Increasing amounts of La(ClO4)3 were added to a 
cuvette containing 50 µL of either i) 3.6 stock solution or i) 3.12 stock solution and a 
buffering solution (0.1 M KCl/0.1 M HEPES). The final concentration of 3.6 and 3.12 was 
2.5 x 10-5 M and 5.0 x 10-5 M respectively. The complexation of the metal ion was 
monitored by the shift in 𝜆9:; from 323 nm to 314 nm for 3.6 and 318 nm to 309 nm for 
3.12.  
3.5.5. 225Ac Sources  
All 225Ac used for Chapter 3 was produced from irradiated thorium (232Th(p,x) 
225/227Ac†), herein referred to as  225/227Ac†. Separation of  225/227Ac†  from irradiated thorium 
(232Th(p,x) 225/227Ac†) was performed as described in Chapter 2. 
3.5.6. 225Ac Radiolabeling Studies  
Stock solutions (1x 10-2 & 1x 10-3  M) of macropa (3.15), DOTA, macrohopo (3.6), 
macropaquin (3.15), and macropaquin-SO3 (3.13) were made with ultra-pure deionised 
water. Serial dilutions were used to prepare initial ligand solutions of 10-4 M, 10-5 M, 10-6 
M, and 10-7 M with ultra-pure water. Concentration-dependent radiolabeling studies were 
performed by the addition of 225/227Ac† (20 – 40 kBq) to a solution containing ligand sock 
(10 µL; or deionized water for negative controls) in a variety of buffers. The actinium 
reaction mixtures were gently agitated using a vortex mixer and the pH was confirmed to 
62 
be between 5 - 11 by spotting a portion (1 - 2 µL) of the reaction mixture on pH paper. The 
radiochemical yield (RCY) was analyzed after 5, 60, and/or 120 minutes at room 
temperature/elevated temperatures. TLC imaging was performed using an AR-2000 
imaging scanner equipped with PD-10 gas, and analysis of RCYs was carried out using 
WinScan V3_14 software. iTLC plate systems are as followed: 
• Method A - aluminum backed silica with citrate buffer (0.4 M, pH 4.0). Free 
225Ac migrates with the solvent front (Rf = 1) while 225Ac-ligand complexes will 
remain at the baseline (Rf = 0).  
• Method B – paper backed iTLC-silicic acid with EDTA (50 mM, pH 7) as mobile 
phase. Free 225Ac migrates with the solvent front (Rf = 1) while 225Ac-ligand 
complexes will remain at the baseline (Rf = 0) 
 
TLC radio-chromatograms of the initial radiolabeling (positive control, labeling, 
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Appendix   
 
1H & 13C NMR Spectra 
 
Figure A1: 1H NMR (400 MHz, DMSO-d6) of 1-hydroxy-6-oxo-1,6-











Figure A2: 13C NMR (101 MHz, DMSO-d6) of 1-hydroxy-6-oxo-1,6-




Figure A3: 1H NMR (400 MHz, DMSO-d6) of 1-(benzyloxy)-6-oxo-1,6-
dihydropyridine-2-carboxylic acid (1,2-HOPO-OBn-Acid, 3.3)  
 
Figure A4: 13C NMR (101 MHz, DMSO-d6) of 1-(benzyloxy)-6-oxo-1,6-
dihydropyridine-2-carboxylic acid (1,2-HOPO-OBn-Acid, 3.3) 
75 
 
Figure A5: 1H NMR (400 MHz, CDCl3) of 2,5-dioxopyrrolidin-1-yl 1-(benzyloxy)-
6-oxo-1,6-dihydropyridine-2-carboxylate (1,2-HOPO-OBn-Succ, 3.4) 
 
Figure A6: 13C NMR (101 MHz, CDCl3) of 2,5-dioxopyrrolidin-1-yl 1-(benzyloxy)-
6-oxo-1,6-dihydropyridine-2-carboxylate (1,2-HOPO-OBn-Succ, 3.4) 
76 
 










Figure A9: 1H NMR (600 MHz, D2O) of 6,6'-(1,4,10,13-tetraoxa-7,16-
diazacyclooctadecane-7,16-dicarbonyl)bis(1-hydroxypyridin-2(1H)-
one) (macrohopo, 3.6) 
79 
 
Figure A10: 13C NMR (151 MHz, D2O) of 6,6'-(1,4,10,13-tetraoxa-7,16-
diazacyclooctadecane-7,16-dicarbonyl)bis(1-hydroxypyridin-2(1H)-
one) (macrohopo, 3.6) 
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Figure A11: 1H NMR (400 MHz, DMSO-d6) of methyl 1-hydroxy-6-oxo-1,6-
dihydropyridine-2-carboxylate, (1,2-HOPO-methylester, 3.7) 
  
Figure A12: 13C NMR (101 MHz, DMSO-d6) of methyl 1-hydroxy-6-oxo-1,6-
dihydropyridine-2-carboxylate, (1,2-HOPO-methylester, 3.7) 
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Figure A13: 1H NMR (500 MHz, CDCl3) of methyl-1-(allyloxy)-6-oxo-1,6-
dihydropyridine-2-carboxylate (1,2-HOPO-allyl-methylester, 3.8) 
 
Figure A14: 13C NMR (126 MHz, CDCl3) of methyl-1-(allyloxy)-6-oxo-1,6-
dihydropyridine-2-carboxylate (1,2-HOPO-allyl-methylester, 3.8) 
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Figure A15: 1H NMR (500 MHz, CDCl3) of 1-(allyloxy)-6-(hydroxymethyl)pyridin-
2(1H)-one (1,2-HOPO-allyl-hydroxide, 3.9) 
 
Figure A16: 13C NMR (126 MHz, CDCl3) of 1-(allyloxy)-6-
(hydroxymethyl)pyridin-2(1H)-one (1,2-HOPO-allyl-hydroxide, 3.9) 
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Figure A17: 1H NMR (500 MHz, CDCl3) of 1-(allyloxy)-6-(chloromethyl)pyridin-
2(1H)-one (1,2-HOPO-allyl-chloride, 3.10) 
 
Figure A18: 13C NMR (126 MHz, CDCl3) of 1-(allyloxy)-6-(chloromethyl)pyridin-
2(1H)-one (1,2-HOPO-allyl-chloride, 3.10) 
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Figure A19: 1H NMR (600 MHz, MeOD) of 6,6'-((1,4,10,13-tetraoxa-7,16-
diazacyclooctadecane-7,16-diyl)bis(methylene))bis(1-
(allyloxy)pyridin-2(1H)-one) (1,2-HOPO-allyl-crown, 3.11) 
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Figure A20: 13C NMR (151 MHz, MeOD) of 6,6'-((1,4,10,13-tetraoxa-7,16-
diazacyclooctadecane-7,16-diyl)bis(methylene))bis(1-
(allyloxy)pyridin-2(1H)-one) (1,2-HOPO-allyl-crown, 3.11) 
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Figure A21: 1H NMR (600 MHz, DMSO-d6) of 6,6'-((1,4,10,13-tetraoxa-7,16-
diazacyclooctadecane-7,16-diyl)bis(methylene))bis(1-hydroxypyridin-
2(1H)-one) (macrohopo’, 3.12) 
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Figure A22: 13C NMR (151 MHz, DMSO-d6) of 6,6'-((1,4,10,13-tetraoxa-7,16-
diazacyclooctadecane-7,16-diyl)bis(methylene))bis(1-hydroxypyridin-
2(1H)-one) (macrohopo’, 3.12) 
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Figure A23:  1H NMR (600 MHz, DMSO-d6) of [La(macrohopo)][ClO4] 
 
Figure A24:  13C NMR (151 MHz, DMSO-d6) of [La(macrohopo)][ClO4] 
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Figure A25:  1H NMR (600 MHz, DMSO-d6) of [La(macrohopo’)][ClO4] 
 




Figure A27:  1H-1H COSY NMR (600 MHz, DMSO-d6) of [La(macrohopo’)][ClO4] 
 
Figure A28:  1H-1H  COSY NMR (600 MHz, DMSO-d6) of [La(macrohopo’)][ClO4] 
in pendant donor arm region 
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Variable Temperature NMR 
  
Figure A29: 1H Varaible Temperature NMR (600 MHz, D2O) of 6,6'-(1,4,10,13-
tetraoxa-7,16-diazacyclooctadecane-7,16-dicarbonyl)bis(1-
hydroxypyridin-2(1H)-one) (macrohopo, 3.6) 
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Figure A31: 1H Varaible Temperature NMR (600 MHz, D2O) of 
[La(macrohopo’)][ClO4] 
 
Protonation Constants  
Table A1: Protonation Constants of macropa, macropaquin and macroquin-SO3 determined 
by pH potentiometry  
 Macropa Macropaquin Macroquin-SO3 
Log Ka1 7.41 10.33 9.34 
Log Ka2 6.89 7.15 9.43 
Log Ka3 3.32 6.97 6.75 
Log Ka4 2.36 3.24 6.62 
Log Ka5 1.69   





Figure A32: Represent the positive control iTLC radio-chromatogram for 225Ac 
radiolabeling  
  




Figure A34: Represent a chelator with ~ 50% RCY iTLC radio-chromatogram for 
225Ac radiolabeling  
